HELP PEOPLE WITH CANCER
LIVE LONGER AND BETTER

3DMed
思路迪

3DMed
思路迪

3D Medicines Inc.

(Incorporated in the Cayman Islands with limited liability)

Stock Code: 1244

2022

Environmental, Social and Governance (ESG) Report

3D Medicines Inc.

TABLE OF CONTENTS

ABOUT THE REPORT

This Environmental, Social and Governance (ESG) Report (hereinafter referred to as the "Report") is the first ESG report released by the Company, mainly disclosing the practices and achievements of the Group in product liability, environmental protection, social welfare, and other aspects in 2022. We hope to present the latest progress of the Company in sustainable development through the Report to shareholders, customers, consumers, employees, governments, partners and other stakeholders.

Reporting Period

The Report covers the period from January 1 to December 31, 2022, with some contents beyond this period.

Important Notice

The Board of Directors of the Company and all the members thereto warrant that the Report includes no false record, misleading statement or material omission, and they are jointly and severally liable for the authenticity, accuracy and completeness of the information contained herein.

Report Scope

The Report covers 3D Medicines Inc. and its subsidiaries.

Basis of Preparation

The Report is prepared in accordance with the provisions of Appendix 27 Environmental, Social and Governance Reporting Guide to the Guide for Main Board Securities Listing Rules issued by the Stock Exchange of Hong Kong Limited.

Data Source

All information and data in the Report originate from the official documents, statistical reports, and financial reports of the Company, as well as ESG information collected, summarized, and reviewed by the Group. Unless otherwise stated, all monetary amounts are in RMB.

Reference Help

For ease of expression, 3D Medicines Inc. is also referred to as "the Company" or "we" in the Report. For more information on company designations and references, please refer to the Referral Table.

Release Form

The Report is provided in traditional Chinese and English for readers. The electronic version of the Report is available at the HKEXnews website (http://www.hkexnews.hk) and the official website of 3D Medicines, Inc. (https://www.3d-medicines.com/).

We value the opinions of stakeholders greatly. Welcome to contact us through the following ways. Your feedback will help us further improve the Report and enhance the overall ESG management performance of the Group.

Tel.: +86(10)6788 8635
E-mail: ir@3d-medicines.com
Mailing address: 7 Liangshuihe 1st Street, Building 3-6, Yizhuang Biomedical Park, BDA, Beijing, China

MESSAGE FROM THE CHAIRMAN

Chairman and CEO
Dr. Zhaolong Gong

The Report is the first ESG report released by 3D Medicines Inc. and presents to stakeholders for the first time our ESG performance and efforts in 2022.

In this era, 3D Medicines remains true to its original aspiration, keeps its mission in mind, and adheres to the concept of sustainable development. It pays high attention to the level of corporate governance, ensures high quality and high standard of R&D and products, and maintains the existing welfare and remuneration system for talents. It actively participates in public welfare activities, protects the environment, and continuously delivers more values for the environment and society.

We have established and continuously improved a complete corporate governance structure, under which the Board of Directors makes annual plans and phased goals and the Management and departments actively implement them to jointly build an effective and complete management system. We have upheld the basic concept of integrity and honesty and strengthened internal control and anti-corruption work, creating a legal and compliant internal growth environment for the Company.

We have continued to enhance our R&D capabilities, established a platform for R&D, clinical application, and commercialization of innovative cancer drugs throughout the entire industry chain, and actively developed and updated cutting-edge laboratory equipment. We have continued to promote R&D team building, introduced experienced talents, strengthened internal and external learning, provided diversified communication and learning opportunities, and offered employees with sufficient practical operation opportunities. While enhancing our internal R&D capabilities, we have utilized our own advantages and actively sought international cooperation opportunities to explore global cutting-edge technologies, accumulate R&D experience, and further improve our R&D and innovation capabilities.

We have always cared about the interests and development of our employees and persisted in the employment concept of legality, diversity, and equality. We have offered competitive and fair remunerations, promotion opportunities and cares for employees, fully safeguarded their legitimate interests, personal privacy, physical health and life safety in daily production and life, and actively given them training through diversified training systems to continuously improve their technical abilities, professional literacy and compliance awareness.

HELPING PEOPLE WITH CANCER LIVE LONGER AND BETTER

We have always prioritized our responsibility as a marketing authorization holder and worked with a responsible attitude toward patients. We have formulated a series of management systems and measures in compliance with relevant drug management laws of the State and based on the actual conditions of the Company, ensuring the quality management system covering the whole process from research, development to commercialization. We have built a service complaint platform and adopted the pharmacovigilance approach to identify and solve problems as early as possible and improve our sensitivity to safety incidents. We have intensified the management of upstream and downstream suppliers, established systems to review suppliers and investigate their backgrounds, fully guaranteeing their quality and preventing various possible risks.

We are fully aware of the significance of environmental sustainability for our businesses, customers, and society. Therefore, we always care about environmental issues and climate changes and are committed to reducing the impact of the Company on the environment. We use sustainable approaches in our daily production, employ environment-friendly technologies and equipment, and promote energy-saving office methods in daily operations to reduce our environmental footprint. We hope to contribute to the society and environment through our actions and enhance our competitiveness and sustainability.

Following the concept of "creating value for society", we actively participate in various public welfare activities and dedicate to making positive contributions to the society. As a socially responsible company, we not only improve our competitiveness continuously, but also make a lot of efforts in giving back to society. We have been long committed to public welfare undertakings such as education and poverty alleviation, with fruitful results. We have made contributions to local education by supporting students in poverty-stricken areas. We have donated drugs in a charitable way to relieve the medical pressure of patients and their families, contributing our own strength to the society.

Looking into the future, we will continue to work in cancer treatment with the support from national policies to the industry, and continue to develop innovative drugs with the vision of **"helping people with cancer live longer and better"** and based on clinical needs. In the mean time, we will fulfill our social and environmental responsibilities, pay back to the society, devote ourselves to public welfare, and receive social supervision and review.

ABOUT THE COMPANY

About us

Founded in 2014, 3D Medicines (1244.HK) is a biopharmaceutical company focusing on the research, development, and commercialization of innovative drugs in the field of managing cancer as a chronic disease. With the vision of "helping people with cancer live longer and better", we develop cancer drugs for all cancer patients in combination with the trend of cancer being managed as a chronic disease. In December 2022, the Company was officially listed on HKEX, stock abbreviation: 3D Medicines, stock code: 01244.HK.

In recent years, with the approach of the era of cancer managed as a chronic disease, the combination of cancer immunotherapy and multiple treatment protocols has significantly improved and extended the life expectancy of patients with various cancers. Envafolimab® (Subcutaneous Injection PD-L1), the Company's first innovative drug, was, approved for marketing in November 2021. As of December 31, 2022, Envafolimab® had been recommended in seven clinical application guidelines. In addition, the Company entered the field of cancer pain management to provide cancer patients with comprehensive long-term treatment plans and better choices to achieve the vision of "reducing the burden of cancer patients and helping them live better".

We believe that the R&D capability of innovative drugs will be a crucial factor in maintaining our industry competitiveness. The Company has established a complete internal R&D system and realized full process coverage from drug discovery, preclinical development, clinical trials, and registration. We have established a platform for drug discovery and transformation research, with continuous R&D in the field of managing cancer as a chronic disease. Relying on our proprietary R&D platform, we can carry out preclinical R&D activities, including drug activity screening, drug cell function research, drug biochemical research, and biomolecule detection. Our R&D centers in Shanghai and Beijing include large and small molecule platforms, cell line screening platforms, and compound screening platforms. We plan to establish an R&D center in the United States in the future.

With high-efficiency clinical development capabilities, the Company adopts the clinical need-oriented and market-driven approach. Our clinical team consists of scientists and doctors with many years of experience in drug development and clinical trial designs targeting patient needs are employed to achieve efficient clinical development of our candidate drugs. Our clinical capabilities can be demonstrated by pushing a new molecular entity (Envafolimab®, Subcutaneous Injection PD-L1) from IND to NDA in only four years. The Company has 12 innovative drug R&D pipelines and carries out over 20 clinical studies. As of December 31, 2022, our R&D team accounted for 61% of the total number of employees in the Company, with 80 holding master's or above degrees, including 17 holding doctoral degrees.

As of December 31, 2022
The R&D team of 3D Med accounted for

61%

Master's degree

80

Doctoral degree

17

In 2022, the Envafolimab Injection was sold around

30

Cities and commercially

200+

Hospital

1,000+

Pharmacie

1,000+

As of December 31, 2022
Sales volume

567 million yuan

The Company is committed to establishing an excellent business team to quickly improve our commercialization capabilities. With the marketing of the Company's first commercialized product, the Company relied on the marketing capabilities of our partners to rapidly commercialize this product, ensuring the speed and efficiency of commercialization promotion, and improving product coverage. In 2022, Envafolimab® was available in 1,000 hospitals and 1,000 pharmacies in more than 200 cities in 30 provinces of China, benefiting over 20,000 patients. As of December 31, 2022, the Company realized sales of RMB 567 million.

We have established qualified sales and promotion departments with rich experience in the commercialization of cancer treatment, dedicated to the commercialization of pipeline products, mainly responsible for product positioning, marketing policies, sales campaign planning, and patient assistance. Our commercialization team conducts contract negotiations, manages distributors and supply chains, and delivers adequate products to patients. Pre-marketing preparations are also gradually being made for other candidate drugs nearly commercialized.

The Company is establishing production facilities and quality management systems that meet international standards to create its own drug production capacity. The Company is constructing internal production facilities in Xuzhou City, Jiangsu Province. The manufacturing system and facilities for the entire drug development process (including chemical and biological agents) comply with good manufacturing practices (GMP) and meet strict standards. To prepare for the large demand for drugs after commercialization, we have purchased land use rights with a total area of 65,637.97m^2 in Xuzhou. We have obtained a construction permit and started constructing new production facilities in Xuzhou City. It is expected to complete the construction and put them into operation by 2024 and they will be sufficient to meet the commercial manufacturing needs of all our pipeline products in the foreseeable future.

The Company was included in the list of stocks under Shanghai-Hong Kong Stock Connect, becoming effective on March 13, 2023. On February 23, 2023, the Company was included by Hang Seng Index Services Limited in the Hang Seng Composite Index as a constituent stock, becoming effective on March 13, 2023. This represents the recognition of the Group's business performance and growth prospects in the capital market.

The Company will continue to be committed to discovering, developing, and commercializing safe and efficient innovative drugs to help cancer patients in need of long-term treatment and strive to achieve the vision of "helping people with cancer live longer and better".

Business summary

A highly collaborative product pipeline, with two-thirds of candidate drugs in the clinical stage

As of December 31, 2022, we have established a pipeline composed of 12 drugs or candidate drugs, of which Envafolimab® (Subcutaneous Injection PD-L1), as our important product, was approved in November 2021, its marketing commercialization was started in the Chinese market, with other seven candidate drugs in the clinical stages.

Envafolimab®, the world's first subcutaneous injection PD-L1 antibody, with excellent sales performance

Envafolimab® is the world's first subcutaneous injection PD-L1 antibody and the first PD-L1 antibody approved in China. It is used the treatment of previously treated microsatellite instability-high (MSI-H)/mismatch repair deficiency (dMMR) advanced solid tumors, addressing the huge unmet medical needs of immunotherapy for patients with venous intolerance. During the reporting period, all of our product sales revenue came from the sales of Envafolimab® in China, at RMB 567 million.

Accelerated global cooperation and developed two globally leading products nearly commercialized

As of December 31, 2022, the Group added 2 clinical trials in Phase III, 2 clinical trials in Phase II, and 3 clinical trials in Phase I and obtained 5 approval notices for clinical trials of drugs. The Group is conducting 4 preclinical trials of candidate drugs.

The Company also completed important milestones in global cooperation. We received the IND approval for Batiraxcept (3D229) and completed the Phase I clinical trial in Chinese healthy volunteers in May 2021. The results were announced at the CSCO Conference in September 2022. In April 2022, we obtained the IND approval to conduct the Phase Ib/II clinical trial in patients with NSCLC, RCC, and UC. In addition, we obtained IND approval in July 2021 to conduct Phase III clinical trial for patients with platinum-resistant ovarian cancer (PROC) in China to participate in a multi-regional clinical trial (MRCT) and launched the trial in China in February 2022. As of December 31, 2022, there were a total of 12 patients enrolled in China.

We obtained IND approval for the **tumor vaccine Galinpepimut-S (3D189)** in China in April 2022 and completed the first Phase I clinical patient administration in China in October 2022, for the treatment of patients with WT1-positive acute myeloid leukemia (AML), multiple myeloma (MM), and non-Hodgkin's lymphoma (NHL) who had completely remitted after completing at least first-line standard treatment, or the patients in the high-risk group with myelodysplastic syndrome (MDS) who had completely remitted or whose optimal treatment response was partial remission.

As of December 31, 2022, the Group added 2 clinical trials in Phase III, 2 clinical trials in Phase II, and 3 clinical trials in Phase I and obtained 5 approval notices for clinical trials of drugs. The Group is conducting 4 preclinical trials of candidate drugs.

Product pipelines

Candidate	Target / Mechanism	Indications/Study Population	Rights	Preclinical Discovery	IND	Phase I	Phase II	Phase III	NDA	Confirma-tory	Partner
Envafolimab	PD-L1	MSI-H/dMMR advanced cancer (mono, 2L+)	Worldwide	China					BLA approved		Alphamab Group,
		Advanced BTC (combo with chemo vs. chemo, 1L)		China							
		NSCLC (vs standard treatment, 1L)		China							
		NSCLC (combo with chidamide, 2L+)		China							Simcere Group, (China,CSO)
		G/GEJ advanced cancer (combo with chemo, 1L)		China			COMPLETED				
		TMB-H advanced cancer (mono, 2L+)		China							
		EC (mono and combo with lenvatinib, 2L+)		China							TRACON (Sarcoma, North America)
		NSCLC, HCC, RCC (combo with lenvatinib)		China							
		HCC, CRC, NSCLC (combo with BD0801)		China							
		Microsatellite stable CRC (combo with cetuximab+/-Fruquintinib, standard treatment failure)		China							
		dMMR advanced solid tumors (mono, 2L+)		MRCT(US、EU、Japan, et.)							
3D189	WT1	Multiple indications	Greater China	China							SELLAS
		AML		China (Directly participated in the MRCT Phase III trial)							
3D229	GAS6/AXL	Healthy Volunteers	Greater China	China		COMPLETED					Aravive
		NSCLC / RCC / UC		China							
		PROC (2L)		China (Directly participated in the MRCT Phase III trial)							
3D1001	COX-2	Post-surgical dental pain/cancer pain	China	China		US					Haihe Biopharma Group
3D1002	EP-4	Cancer pain / osteoarthritis	China	China		US					
3D185	FGFR1/2/3	Locally advanced or metastatic solid tumors	Worldwide	China/US							Haihe & SIMM
3D011	TKI prodrug	Advanced malignant solid tumors	Worldwide	China							-
3D197	CD47	Multiple indications	Greater China	China							ImmuneOncia
3D057	CD3+PD-L1	Multiple indications	Greater China Worldwide Priority Transfer right	China							Y-Biologics
3D059	WT1	Multiple indications	Greater China	China							SELLAS
3D060	Sema4D	Multiple indications	Worldwide	China/US							-
3D062	KRAS	Multiple indications	Worldwide	China/US							-

pivotal trial

First commercialized product Envafolimab® (Subcutaneous Injection PD-L1)

Envafolimab® is a fusion protein of a single-domain PD-L1 antibody, injected subcutaneously for the treatment of malignant tumors, which has been approved in China for the treatment of previously treated MSI-H/dMMR advanced solid tumors.

Sustainable revenue from successfully explored business model

As of December 31, 2022, our revenue from the sales of Envafolimab® in China was RMB 567 million.

One supplementary application approved by National Medical Products Administration

On August 19, 2022, the National Medical Products Administration (NMPA) approved the Envafolimab® NDA supplementary application of "a dose of 300mg every two weeks". This approval was based on our clinical pharmacology data in China, the United States, and Japan. The approval of this treatment plan will significantly reduce the frequency of drug use, improve patients' convenience, and provide better treatment options for cancer patients.

10 clinical trials of Envafolimab® conducted, including 2 new registered clinical trials approved by NMPA and FDA

- The last subject who had completed Phase 1b was enrolled for the multi-site, open-labeled Phase Ib/II clinical study to treat advanced solid tumors in combination with Lenvatinib Mesilate.
- The first subject was enrolled for the Phase II clinical study of advanced non-MSI-H/non-dMMR endometrial cancer with at least first-line platinum-containing chemotherapy failure or intolerance for the treatment in combination with Lenvatinib Mesilate.
- The planned interim analysis was completed in the open, single-arm, and multi-site Phase II clinical study for the mono treatment of patients with advanced solid tumors. According to the suggestions of IDMC, the enrollment of subjects with TMB<12 could be terminated and the subjects with TMB ≥ 12 could be enrolled as expected in this study.
- The last subject was enrolled for the Phase II study on the treatment of resistant non-small cell lung cancer treated with PD-1 inhibitor in combination with Chidamide and the trial is under subject follow-up as planned.
- The Phase 3 trial in combination with chemotherapy compared to first-line chemotherapy for advanced biliary tract cancer is ongoing.
- The open, multi-queue, and multi-site Phase II clinical study of BD0801 (for combined injection) combined/not combined with chemotherapy for patients with advanced solid tumors is ongoing smoothly.
- In September 2022, the combined treatment clinical trial of Envafolimab® and Erbitux® was approved to evaluate the clinical efficacy of RAS/BRAF wild-type and non-MSI-H/p-MMR metastatic colorectal cancer patients not treated with Fluorouracil, Oxaliplatin, Irinotecan, and Bevacizumab (excluding patients with Bevacizumab contraindications and patients who are not suitable to be treated with Bevacizumab according to treatment guidelines and those who cannot be treated with Bevacizumab due to economic reasons).
- In December 2022, it was approved by the FDA to conduct the global multi-site and single-arm Phase II clinical study on the efficacy and safety of Envafolimab® mono treatment of advanced solid tumors of dMMR, with a dose of 600mg subcutaneous injection every three weeks.



Recommendations for clinical application

Since marketing, our Envafolimab® (Subcutaneous Injection PD-L1) has been widely recognized by professional institutions. Since 2022, it has been included in six CSCO guidelines and one guideline of the China Anti-Cancer Association.

Since marketing, our Envafolimab® (Subcutaneous Injection PD-L1) has been widely recognized by professional institutions. Since 2022, it has been included in six CSCO guidelines and one guideline of the China Anti-Cancer Association.

- 2022 Edition of CSCO Clinical Guidelines for the Diagnosis and Treatment of Gastric Cancer (Class 2A evidence, Level I recommendation, recommended for dMMR/MSI-H populations not treated with PD-1/PD-L1 monoclonal antibodies (regardless of HER2 status));
- 2022 Edition of CSCO Guidelines for the Diagnosis and Treatment of Colorectal Cancer (Class 2A evidence, Level II recommendation, recommended for MSI-H/dMMR advanced colorectal cancer patients of the second and third lines not treated with immune checkpoint inhibitors);
- 2022 Edition of CSCO Guidelines for Clinical Application of Immune Checkpoint Inhibitors (Class 2A evidence, Level I recommendation, recommended for MSI-H/dMMR advanced solid tumor patients of the second line and above);
- 2022 Edition of CSCO Guidelines for the Diagnosis and Treatment of Endometrial Cancer (Level II recommendation, used for biomarker-guided second-line system treatment of recurrent and metastatic endometrial cancer);
- 2022 Edition of CSCO Guidelines for the Diagnosis and Treatment of Cervical Cancer (Level II recommendation, used for second-line treatment of recurrent and metastatic cervical cancer);
- 2022 Edition of CSCO Guidelines for the Diagnosis and Treatment of Ovarian Cancer (Class 2B evidence, Level III recommendation, (1) used for evaluating the treatment of MSI-H/dMMR platinum-sensitive recurrent ovarian epithelial cancer with the inability to achieve satisfactory tumor reduction through surgical resection, (2) used for evaluating the treatment of MSI-H/dMMR platinum-resistant recurrent ovarian epithelial cancer with the inability to achieve satisfactory tumor reduction through surgical resection);
- 2022 Edition of Chinese Guidelines for Radiotherapy of Esophageal Cancer (the Phase II/III clinical study of many PD-1/PD-L1 antibodies including ChiCTR2100051606 (Envafolimab) combined with synchronous radiochemotherapy for locally advanced non-surgical esophageal squamous cell carcinoma is ongoing, preliminarily confirming effectiveness and safety of radiotherapy combined with immunotherapy).

Patents

On June 14, 2022, the Canadian Intellectual Property Office granted a Canadian patent of Envafolimab® (Subcutaneous Injection PD-L1).

Academic publications

The recent academic publications about Envafolimab® (Subcutaneous Injection PD-L1) include:

- Markham A. Envafolimab: First Approval. Drugs. 2022;82(2):235-240. doi:10.1007/s40265-022-01671-w
- Shimizu T, Nakajima TE, Yamamoto N, et al. Phase I Study of Envafolimab (KN035), a Novel Subcutaneous Single-domain Anti-PD-L1 Monoclonal Antibody, in Japanese Patients with Advanced Solid Tumors. Invest New Drugs. 2022; 40(5):1021-1031. doi:10.1007/s10637-022-01287-7
- Shen L, Li J, Deng Y H, et al. Critical Phase II Study Data Update and Subgroup Analysis of Envafolimab in the Treatment of MSI-H/dMMR Advanced Solid Tumors.(Paper Collection of 2022 Academic Annual Conference of CSCO)
- Liu R Y, Yin X L, Deng Y H, et al. Safety and Efficacy of Envafolimab Combined with FOLFOX as First-line Treatment in Patients with Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma in a Phase II Clinical Trial (Chinese Journal of New Drugs)
- Xu J, Papadopoulos K P, Shimizu T, et al. Efficacy of Envafolimab, a Novel Subcutaneous Anti-PD-L1 Inhibitor, in Patients with Advanced Solid Tumors: Pooled Results from Three Phase 1 Studies. Paper Collection of 2022 Academic Annual Conference of CSCO

Batiraxcept (3D229)

3D229 is a high-affinity, soluble Fc-fusion protein designed to block the activation of the GAS6-AXL signaling pathway by intercepting the binding of GAS6 to its receptor AXL. We were approved to conduct the Phase I clinical trial in Chinese healthy volunteers in May 2021, completed the clinical trial in May 2022, and announced the results at the CSCO Conference in September 2022. In April 2022, we obtained the IND approval to conduct the Phase Ib/II clinical trial in patients with NSCLC, RCC, and UC.

In addition, we obtained the approval to conduct multi-regional clinical trials on patients with PROC in China in July 2021 and launched the trial in February 2022. As of December 31, 2022, 12 patients from China had joined the clinical trial.

In November 2022, our partner Aravive announced that Batiraxcept had been granted the Fast Track qualification status by the FDA for the treatment of patients with advanced or metastatic clear cell renal cell carcinoma (ccRCC) who had developed disease progression after receiving first or second-line systemic treatment. In December 2022, CDE approved our CMC sIND change application. With this approval, 3D229 samples produced by the new process could be used for clinical research.

As of the date of this announcement, Aravive is evaluating the Phase III critical trial for the treatment of PROC with 3D229 in the United States and Europe and enrollment has been completed.

Tumor vaccine Galinpepimut-S (3D189)

3D189 is a peptide cancer vaccine targeting the WT1 protein, which is present and overexpressed in a range of hematological malignancies and solid tumors. 3D189 has been granted the Fast Track qualification and orphan drug qualification by the FDA for the treatment of acute myeloid leukemia (AML).

We obtained the IND approval for 3D189 in China in April 2022. In October 2022, we completed the clinical administration in China in the first case of WT1 positive AML patients who had completely remitted after completing at least first-line standard treatment, or the first case of patients with multiple myeloma (MM), non-Hodgkin's lymphoma (NHL) or high-risk myelodysplastic syndrome (MDS) in China who had completely remitted or whose optimal treatment response was partial remission.

Our partner SELLAS Group completed the Phase II trial for AML patients with first complete remission, and the results showed that the median overall survival (OS) of patients in the maintenance treatment group was 67.6 months (all age groups), representing a significant improvement compared to optimal standard treatment. The results also showed that compared with patients without immune response, patients who received immune response using Galinpimut S (GPS) showed an improvement trend in clinical outcomes.

We produced the clinical batch of 3D189 API in China in October 2022. As of the date of this announcement, SELLAS Group is conducting the Phase III critical trial in the United States and Europe to evaluate the efficacy of 3D189 in the treatment of AML. In addition, we have obtained an exclusive license for the development, manufacturing, and commercialization of 3D189 in Greater China.

As of the date of this announcement, SELLAS Group is conducting the Phase III critical trial in the United States and Europe to evaluate the efficacy of 3D189 in the treatment of AML.
The Company expects to join the trial in 2023.

3D011

Self-developed prodrug of tyrosine kinase inhibitor (TKI)

3D011 is a tyrosine kinase inhibitor (TKI) prodrug independently developed by the Company, which will be used as a monotherapy and developed in combination with other drugs for the treatment of solid tumors. We obtained the IND approval from NMPA in January 2021 and launched this Phase I clinical trial in February 2022. On June 7, 2022, a US patent for 3D011 was granted by the United States Patent and Trademark Office. On December 28, 2022, a European patent for 3D011 was granted by the European Patent Office. As of the date of this announcement, we are conducting open-label and single-arm Phase I dose escalation and dose expansion clinical trials for patients with advanced solid tumors.

3D185

Synchronized Phase I clinical trials in China and the U.S.

3D185 is an inhibitor of fibroblast growth factor receptor (FGFR) 1-3 and colony-stimulating factor 1 receptor (CSF1R). In January 2018, the IND approval was obtained from NMPA. We obtained the IND approval from FDA in September 2019. In August 2021, Phase I clinical trials for patients with advanced solid tumors were completed in China and the United States. In October 2022, 3D185 was certified by the FDA as an orphan drug for the treatment of biliary tract cancer. On January 13, 2023, 3D185 was designated by the FDA as an orphan drug for the treatment of gastric cancer and gastroesophageal junction cancer.

In order to better explore and protect more dosage forms of the FGFR inhibitor, we submitted a Chinese patent application to the China National Intellectual Property Administration on December 1, 2022. As of the date of this announcement, a new preparation of 3D185 is being studied in Phase I clinical trials in China and the United States.

3D1001

Fast-acting, long-lasting analgesic painkiller

3D1001 is a new-generation cyclooxygenase-2 (COX-2) inhibitor with good pharmacokinetic characteristics in clinical studies, which has a rapid effect on patients with postoperative toothache and prolongs the analgesic time. In February 2019, the IND approval for 3D1001 was obtained from NMPA.

In order to establish the intellectual property rights of compound crystallization, we submitted a Chinese patent application to the China National Intellectual Property Administration on December 27, 2022. As of the date of this announcement, we have produced the API of the clinical batch for Phase I/II clinical trials. 3D1001 is a potential drug for the treatment of inflammatory pain and will become our next candidate drug for critical clinical trials and commercialization.

3D1002

Treat tumor pain and reduce toxic side effects

3D1002 is an e-type prostanoid receptor 4 (EP4) antagonist. We obtained IND approval from NMPA in July 2018. As of the date of this announcement, we have produced the drugs of the clinical trial batch, and 3D1002 is a potentially effective target for treating tumor pain and is in the clinical trial stage.

3D197

Next-generation CD47

3D197 is a next-generation fully humanized anti-CD47 IgG4 monoclonal antibody. In January 2022, the IND approval for 3D197 was obtained from NMPA to evaluate the efficacy of 3D197 combined with Envafolimab®, Azacitidine, Rituximab, and other therapies in the treatment of solid tumors and hematological malignancies.

Preclinical candidate drugs

Mature target, innovative drug candidate

In addition to clinical stage candidate drugs, we are also evaluating many preclinical stage candidate drugs in the pipeline, including (a) 3D057, a bispecific antibody drug, targeting CD3 receptors on T cells and PD-L1 on tumor cells, (b) 3D059, next-generation tumor vaccine immunotherapy, targeting WT1 protein in hematological malignancies and solid tumors, (c) 3D060, our internally developed monoclonal antibody, targeting Semaphorin 4D (Sema4D) in tumor cells, and (d) 3D062, our internally developed small molecule for KRAS mutant patients. For our internally developed 3D062, we submitted two Chinese patent applications on January 20, 2022 and April 8, 2022, respectively, and one PCT application on December 1, 2022.



Social recognition

Wall of Honors in 2022

3D Medicines (Beijing) Co., Ltd. was certified as one of the Fourth Batch of Specialized, Refined, Differentiated, and Innovative SMEs in Beijing in 2022.

3D Medicines (Beijing) Co., Ltd. was certified by the National High-tech Enterprise Certification Management Leading Group Office as a "High-Tech Enterprise" again.

3D Medicines (Shanghai) Co., Ltd. was certified by the National High-tech Enterprise Certification Management Leading Group Office as a "High-Tech Enterprise" among the second batch in 2022.

3D Medicines (Shanghai) Co., Ltd. was awarded the title of 2022 Zhangjiang Life Science Industry New Prominent.

3D Medicines (Sichuan) Co., Ltd. was certified as one of the Seventh Batch of Small and Medium-sized Technological Enterprises in 2022.

3D Medicines (Sichuan) Co., Ltd. was certified as one of the Specialized, Refined, Differentiated, and Innovative SMEs in Sichuan Province in 2022 and a Leading Enterprise in the Circle Construction and Chain Enhancement of Industries in Jinniu District.

3D Medicines received the 2022 "GuruClub Golden Award · Annual Most Valuable IPO Enterprise" by GuruClub.

3D Medicines received the 2022 "Golden Wisdom Award · Award for Excellence in Pharmaceutical and Biological Industry" from the financial circle.

3D Medicines was included in the List of Top 100 Chinese Pharmaceutical Innovation Enterprises 2022.

Envafolimab® was selected by People's Daily Health Client as one of the "Top 10 New Drugs of the 14th Health China Forum".

Events in 2022

January 2022

A clinical trial approval notice issued by NMPA was obtained for the clinical trial of new generation CD47 antibody 3D197 Injection.

The clinical trial application for the tumor vaccine 3D189 (Galinpepimut-S, abbreviated as GPS) was accepted by NMPA.

February 2022

The IND application of a multiple-site and open-label Phase Ib/II clinical study of Batiraxcept (3D229) injection combined with Envafolimab® or Lenvatinib to treat advanced solid tumors was officially accepted by the Center for Drug Evaluation of NMPA (CDE).

The Phase III clinical trial of Batiraxcept (3D229) was launched in China. As of December 31, 2022, there were a total of 14 patients enrolled in the MRCT in China.

April 2022

The drug clinical trial approval notice issued by NMPA was obtained for the tumor vaccine 3D189 (Galinpepimut-S, abbreviated as GPS).

The CDE approved the IND application of a multiple-site and open-label Phase Ib/II clinical study of Batiraxcept (3D229) injection combined with Envafolimab® or Lenvatinib to treat advanced solid tumors.

May 2022

The first patient was enrolled for the Phase II clinical trial of the tumor vaccine 3D189 (Galinpimut S, abbreviated as GPS) combined with Lenvatinib for the treatment of endometrial cancer.

The results of the Phase II clinical study of Envafolimab® (Subcutaneous Injection PD-L1) combined with FOLFOX were first published online in the Chinese Journal of New Drugs in Volume 31, Issue 13, 2022.

June 2022

A clinical trial was conducted for Envafolimab® (Subcutaneous Injection PD-L1) combined with Merck's EGFR inhibitor Erbitux® (Cetuximab Solution for Infusion) to treat RAS/BRAF wild-type, non-MSI-H/pMMR, and metastatic colorectal cancer patients who failed in standard treatment.

August 2022

A supplementary application for Envafolimab® (Subcutaneous Injection PD-L1) of "a dose of 300mg every two weeks" was approved by NMPA.

September 2022

Envafolimab® (Subcutaneous Injection PD-L1) was qualified for the FDA Fast Track for the treatment of soft tissue sarcoma indications.

October 2022

The first patient was enrolled in the Institute of Hematology & Blood Diseases Hospital, Chinese Academy of Medical Sciences for the Phase I clinical trial of the tumor vaccine 3D189 (Galinpepimut-S, abbreviated as GPS).

3D185 was certified as an orphan drug for the treatment of biliary tract cancer.

November 2022

The results of three Phase I clinical trials of Envafolimab® (Subcutaneous Injection PD-L1) conducted in China, the United States, and Japan for the treatment of patients with advanced refractory solid tumors were obtained.

The data update and subgroup analysis of subjects with advanced solid tumors of MSI-H/dMMR treated with Envafolimab® (Subcutaneous Injection PD-L1) after a follow-up of 26.8 months were reported at the CSCO Conference.

3D Medicines announced the Phase I clinical study of the Anexelekto (AXL) inhibitor Batiraxcept (3D229) in healthy Chinese subjects for bridging purposes at the 25th Annual Conference of the Chinese Society of Clinical Oncology (CSCO).

December 2022

The Company was officially listed on HKEX, company abbreviation: 3D Medicines, company code: 01244.HK.

An official notice of IND from the FDA was obtained for Envafolimab® (Subcutaneous Injection PD-L1) to conduct the Phase II clinical trial in the treatment of advanced solid tumors of dMMR.

CORPORATE GOVERNANCE

In 2022, the Company had seven directors, including one executive director, three non-executive directors, and three independent non-executive directors, of whom three are doctorate degree holders, and one is female.

Director

7

Executive director

1

Non-executive director

3

Independent non-executive director

3

Members holding doctoral degree

3

Female director

1

CORPORATE GOVERNANCE

Internal governance

In 2022
3D Med had Director

7
Executive director

1
Non-executive director

3
Independent non-executive director

3
Members holding doctoral degree

3
Female director

1

We are well aware that a good corporate governance structure is an important foundation for our success. Therefore, we have adopted a corporate governance structure that conforms to international best practices to ensure that our management behavior meets the highest standards and safeguards the rights and interests of our shareholders and investors. During our operation, 3D Medicines always adheres to the Securities Law of the People's Republic of China and the Listing Rules and the Code of Corporate Governance for Listed Companies of HKEX.

The Board of Directors of the Company is the core body of corporate governance, consisting of the Chairman, independent directors and non-independent directors. The independent directors account for more than one-third of the Board of Directors. The Board of Directors has three committees including the Audit Committee, the Remuneration Committee and the Nomination Committee to oversee the conduct of the Company's management and ensure the long-term development of the Company. Attaching great importance to the professional background and industry experience of the members composing the Board of Directors, the Company had 7 directors in 2022, including 1 Executive Director, 3 Non-executive Directors and 3 Independent Non-executive Directors, 3 of whom had doctoral degrees and 1 of whom was a female director. With rich industry experience and advantages in their respective fields, the members composing the Board of Directors of the Company can make correct decisions for the comprehensive development of the Company.



In addition, the Company has an internal audit department that oversees the Company's internal control and risk management. While implementing risk management training, strengthening the ability of front-line personnel to identify and manage risks and allocating internal control and risk management professionals to review and control relevant projects, the Audit Committee under the Board of Directors will review and manage the overall internal control mechanism and risk management mechanism, and evaluate and make decisions on major events or projects, so as to improve the Company's internal control level and reduce risks through various efforts and ensure that shareholders' rights and interests are not damaged.

The Company regularly discloses the Company's information by announcements in the form of financial reports and other relevant means, including but not limited to disclosure of the Company's financial status, business, operations, corporate governance structure, inside information and risk factors. In addition, the Company provides investors with transparent information on the Company's operation to ensure the transparency and fairness of the capital market, thereby ensuring the rights and interests of investors and shareholders of the Company.

ESG Governance

Committed to sustainable development, the Company attaches importance to ESG. The Company is establishing and improving a complete ESG management system by carrying out a series of positive attempts and management with a responsible attitude towards society and the environment upheld. At the same time, the Company extensively communicates with stakeholders, listens to opinions, sets goals, and continuously optimizes the ESG management system to improve the level of ESG management.

Statement of the Board of Directors on ESG

Board of Directors
Supreme responsible and decision-making body for ESG work

↓

Analyze the development of the industry
Inspect the internal management from an objective point of view
Identify overall ESG risks and opportunities

↓

Board Office
Preside over ESG management

↓

Establish an effective contact mechanism with various stakeholders, and conduct regular communication to understand internal and external opinions, suggestions and requirements.

Adhering to the vision of "helping people with cancer live longer and better", "prolonging the survival time of cancer patients and improving the quality of life of patients" as its corporate mission, the Company takes clinical needs as the guide, innovation and R&D capabilities as the engine to constantly discover, develop and commercialize safe and efficient innovative drugs to help cancer patients who need long-term treatment. Paying full attention to ESG, the Company implements responsible management.

The Company focuses on balancing business growth with ESG needs to achieve sustainable development, improve internal operation and management capabilities, actively participate in public welfare undertakings and build an environmentally friendly corporate framework, striving to create maximum value for stakeholders.

As the highest responsible and decision-making body for the Company's ESG work, the Board of Directors will pay close attention to the Company's ESG management, analyze the development of the industry, objectively examine the internal management and identify the overall ESG risks and opportunities.

The Board Office presides over ESG management, establishes an effective contact mechanism with various stakeholders, and conducts regular communication to understand internal and external opinions, suggestions and requirements. In addition, it identifies significant ESG issues and fully considers the above factors when developing, adjusting and implementing ESG policies.

The Report discloses in detail the progress and outcome of the Company's ESG work in 2022. The Report was approved by the Board of Directors on March 30, 2023.

ESG management architecture

The ESG management framework is managed by the Company's Board of Directors, which is responsible for ESG risk identification, assessment and response strategy development, ESG policy review, ESG annual plan development and target achievement review, ESG work monitoring, etc., and assumes full responsibility for ESG strategy development and result reporting.

The Board Office is responsible for implementing the overall ESG plan, developing ESG assessment targets, assisting various departments in evaluating ESG risks, and establishing effective feedback and communication mechanisms.

The ESG team is responsible for implementing relevant ESG work planning, collecting, collating and reporting ESG-related matters in the Company's operation, and for public disclosure of ESG.

All business and functional departments cooperate with the ESG team to implement ESG targets and ESG-related work.

Board of Directors	Board Office	ESG work team
Decision-making body	Supervisory Organization	Execution departments
• Review the implementation of the Company's ESG work • Develop ESG sustainable strategies and related targets	• Identify and evaluate the Group's ESG-related content, including the development strategy and targets proposed by the Board of Directors • Monitor daily ESG performance and implementation • Predict and evaluate ESG risks and establish an effective communication mechanism	• Regularly collect, collate and report ESG-related matters during the Group's operation • Publicly disclose ESG

ESG strategic planning and overall targets

In addition to developing emission management and resource management targets, the Company has set up seven major ESG company development planning directions such as ESG, innovative R&D, product responsibility, responsible operation, people first, public welfare undertakings and environmental protection for various ESG-related matters and set targets respectively to establish a comprehensive and complete ESG management and development system according to the development planning and actual situation this year.

ESG management targets

Although we know the fact that identifying and prioritizing ESG-related issues are dynamic and ongoing processes for the year, we have set the following targets as our top priorities:

Issues	ESG management in 2022	Targets of ESG management in 2023
ESG Governance	An ESG management structure has been established with the Board of Directors as the decision-making body, the Board Office as the supervisory body and the ESG team as the executive body, and all departments of the Company cooperate in implementing the ESG management. Substantive analysis has been conducted to identify common issues of the Company. Contacts with various stakeholders have been established and a contact mechanism has been established.	The Board of Directors deeply guides the achievement of ESG-related work targets, further establishes and improves the Company's existing ESG management system and deliberates ESG matters in the Board of Directors.
Innovative R&D	The pipeline is progressing smoothly and rapidly, and an advanced technical platform has been established for business training. Exploratory clinical trials have been conducted in cooperation with international pharmaceutical companies.	Further optimize the R&D management system, accelerate the listing process of innovative drugs, and strengthen the management and control of drug safety and quality. Optimize and improve the intellectual property management system and risk management mechanism. Continue to actively expand international cooperation and cooperate in exploring cutting-edge drug development pipelines.
Product liability	Establish an effective product responsibility system to ensure that there are policies and systems in terms of product quality and safe production and that each production quality department works in an orderly manner in accordance with regulations. Establish recall measures and return management procedures, as well as measures for managing adverse events. Establish a supplier management system and develop management systems for each supplier.	Optimize and improve compliance management systems such as compliance system, training system, supervision system and assessment management. Establish production and safety management systems and methods. Optimize measures for abnormal events and product recalls and improve after-sales service. Ensure efficient cooperation between upstream and downstream enterprises an strengthen the quantitative and scientific management of supply. Strengthen open and procedural measures for supplier management.
Responsible operation	Establish internal compliance management system and measures, and fair competition system and policy have been developed. Integrity practice system policy, internal audit system and policy have been developed. Reporting channels, anti-corruption, clean government and internal control management training have been set up.	Continue to attach great importance to and implement the responsibility of operation and management, and establish and improve the responsible operation and management system. Establish a business ethics management system.
People first	Ensure legal employment, protect the health and safety of employees and help employees grow and develop their careers by standardizing the system, diversifying salary and benefits and providing professional training.	Remain committed to ensuring legal employment, protecting the health and safety of employees, and providing strong support for their career development.
Public service	Actively fulfill social responsibilities and carry out public welfare activities such as charitable drug donation and donation for educational assistance. Establish the "3D Medicines Student Assistance Fund".	Continue to actively participate in social welfare undertakings, establish communication channels with the society and the public, and increase sensitivity to public social responsibility.
Environmental protection	Create a green office environment through continuous promotion of low-carbon concepts within the Company; optimize and upgrade laboratory equipment and facilities to achieve energy saving, emission reduction, sound insulation and noise reduction, and reduce the impact on the surrounding environment based on the actual operation situation.	Reduce the consumption density level of electricity and water; Advocate green office, make full use of natural lighting, and provide air conditioning energy-saving solutions; Strictly abide by the implementation standards of laboratory "three wastes" treatment.

Communication with stakeholders

Stakeholders	Expectation and requirements	Communication mode
Government and supervisory body	Compliant operation Drug quality and safety Anti-corruption Local employment promotion Clean production	Government communication Information disclosure Meetings and visits Communicate with the medical department Compliance reports
Shareholders and investors	Compliant operation Operating performance Risk control Information disclosure Return on investment	General Meeting of Shareholders Investor roadshow Company website Prospectus Other information disclosure
Customers	Drug safety and quality Customer rights and privacy protection Drug R&D and innovation Responsible marketing	Customer service Daily operations/communication Company website Academic conferences Industry forums
Partners	Win-win cooperation Sustainable development of supply chain Product and service quality	Daily communication and dialogue Audit and evaluation
Employees	Protection of employees' rights and interests Occupational health and safety Employee training and career development	Occupational, health, and safe training Employee care activities Internal training and learning Team building activities Performance evaluation
Industry associations	Fair competition Promotion of industry development Technology and experience sharing	Industry exchange Strategic cooperation Professional forums
Community representative	Promotion of local economic development Community service Public charity	Public welfare activities Community activities

Substantive topics

The Company collects substantive topics related to the Group in accordance with the new requirements of the ESG Reporting Guidelines of the Stock Exchange and with reference to relevant international general initiatives and standards, as well as ESG issues with the general concern of the industry. After actively soliciting the opinions of various experts and actively communicating with various stakeholders, the Company selected 15 substantive topics related to its business development direction.

Highly substantive topics	Moderate substantive topics	Mild substantive topics
Intellectual property protection	Employee rights and benefits	Social public welfare investment
R&D and innovation	Resource management	
Business cooperation	Employee training	
Employee health and safety	Employment, equality and diversity	
Quality management	Emission management	
Compliant operation	Responsible marketing	
Supply chain management		

Substantive topic matrix of the Company



Highly important topics

16.R&D and innovation
27.Protection of the interests of shareholders and investors
17.Intellectual property protection
7.Optimized resource management
9.Employee health and safety
20.Drug quality management
8.Employee rights and interests
2.Management of hazardous emissions
6.Response to climate change
5.Energy saving
18.Supply chain management

Moderate important topics

22.Responsible marketing
14.Legal employment, equality and diversity
3.Chemical drug management
26.Risk control
25.Legal and compliant governance
11.Employee welfare and care
24.Economic benefits and financial performance
15.Customer service guarantee
1.Sound environmental management system
28.Anti-corruption and clean government
10.Employee communication
19.Win-win cooperation
4.Water resource utilization
12. Employee training
13.Employee salary
23.Social public welfare investment

General important topics

21. Information security and privacy protection

INNOVATIVE R&D

In 2022, the Company owned 12 R&D pipelines of new medicines and developed 25 test items, including five registered clinical studies.

Accumulative number of licensed intellectual property rights of the Group

Patent	Registered trademark	Copyright
25	71	28

In 2022, our first commercial product Envafolimab® (IH PD-L1) was available in 1,000 hospitals and 1,000 pharmacies in more than 200 cities of 30 Chinese provinces (covered by the Huimin Bao Insurance in 17 cities), with an annual sales amount of RMB 567 million.

INNOVATIVE R&D

As a biological innovative drug company with the whole industry chain, the Company has always taken innovation and R&D as important factors for the Company's development and competitiveness. Adhering to the concept of "helping people with cancer live longer and better", the Company remains its original intention centered on the field of chronic cancer treatment unchanged. While working tirelessly, constantly optimizing the internal R&D system, reasonably increasing R&D investment and building an advanced test platform, the Company pays attention to international strategic cooperation and cooperation with scientific research institutions. In addition, the Company constantly improves the level of R&D and helps the coordinated development of the industry in combination with actual clinical needs.

R&D system and management

R&D construction

The Company attaches great importance to the construction of R&D team. As of December 31, 2022, the R&D team of the Company accounted for 61% of the total number of employees in the Company, with 80 holding master's or above degrees, including 17 holding doctoral degrees.

As an innovative drug R&D company, the Company has achieved full chain coverage including drug discovery, preclinical study, clinical trials and registration. The Company has established study centers in Beijing and Shanghai. With hundreds of commercial cancer cell lines from the world's four largest cell banks including ATCC, ECACC, JCRB and RIKEN, the Company can provide broader, more effective and more convenient candidate drug screening in early preclinical development.

Relying on the Company's mature and experienced clinical R&D team, the Company's innovative drug R&D pipeline is progressing rapidly. Based on Envafolimab® (subcutaneous PD-L1), the Company has built an innovative drug pipeline matrix with product co-use potential. At the same time, the Company continues to rapidly progress preclinical candidate compounds into clinical practice. As of December 31, 2022, the Group has added 2 clinical trials in Phase III, 2 clinical trials in Phase II, 3 clinical trials in Phase I and 4 pre-production candidate drug trials and obtained 5 approval notices for clinical trials of drugs.

As of December 31, 2022
The R&D team of 3D Med accounted for

61%

Master's degree

80 people

Doctoral degree

17 people



Laboratory

Intellectual property management

The patents of the Company exclusively cover compound molecules, preparations, crystal forms, preparation processes, etc. of the Company's products. The Company is committed to respecting and protecting all intellectual property rights related to the Group's business while avoiding infringement of others' intellectual property rights.

In 2022, the Company standardized the internal operation process of the department and improved the Patent Management System. In addition, the Company improved the patent application approval process and patent search approval process, ensuring the timeliness, accuracy and comprehensiveness of the patent application from the process and procedure.

Overall situation of the Company's intellectual property:

	Patents (Nr.)	Registered trademark (Nr.)	Copyright (item)
Accumulated acquisition of intellectual property rights authorization by the Group	25	71	28
New intellectual property application by the Group in 2022	5	23	0
New intellectual property authorization to the Group in 2021	7	28	24

In 2022, the Company further improved the intellectual property training system to enhance the awareness of the employees' intellectual property protection in a diversified way, including training employees on knowledge related to intellectual property throughout the Company and explaining the knowledge related to intellectual property to each department according to different situations and the needs of relevant departments, so as to improve the understanding of the employees' intellectual property protection and risk prevention and control awareness.

Patent wall

R&D management

The Company strictly adheres to laws, regulations and industry standards such as the Provisions for Drug Registration (2020), Good Clinical Practice (2020) and Declaration of Helsinki in clinical studies and has developed internal specifications for R&D incentives, emergency response plans for clinical trials, laboratory management, etc.

The Group attaches great importance to product evaluation and tracking management to provide patients with more detailed and instructive drug information. In 2021, in the clinical study stage, the Group conducted a detailed study on the indications of drugs, filed each indication before marketing the product, and obtained supplementary approval from the National Medical Products Administration, including the notice of approval for supplementary applications of adverse reactions, clinical trials, pharmacology and toxicology.

R&D training

Strong scientific research capabilities need to be based on excellent R&D teams. To improve R&D efficiency, the Company trains R&D teams in various forms to strengthen professional capabilities.

In 2022, the Company's internal management, scientists and professional and technical employees shared high-quality R&D experience through internal academic discussions, professional technology sharing, industry analysis, R&D experience sharing, etc. In addition, the Company supports the R&D personnel to actively participate in various academic conferences and learn cutting-edge technical theories.

In 2022, the average duration of the Company's annual R&D training was 1 to 1.5 hours. A total of 32 training sessions were held, where the total R&D training duration was 48 hours. The average number of attendees per session was 150, and the average employee coverage rate was more than 60%.

In 2022
3D Med's average annual time for R&D training

1.5 hours

Total training session

32 sessions

Total hours of R&D training

48 hours

Trainees per session

150 trainees



Industry co-construction and business cooperation

Cooperative projects
Merck (March 2022)
Cooperative fields
Clinical cooperation
Scope of cooperation
The clinical trials for the combination therapy of Envafolimab® with Erbitux® (Merck's EGFR (epidermal growth factor receptor) inhibitor) were approved by IND to evaluate the clinical effect of the combination in RAS/BRAF wild-type and non MSI-H/pMMR patients with metastatic colorectal cancer who have failed in treatment with fluorouracil, oxaliplatin, irinotecan and bevacizumab (except those who have bevacizumab treatment contraindications, who are not suitable for bevacizumab according to the treatment guidelines or cannot receive bevacizumab treatment due to economic reasons).

The Company is committed to exploring and seizing the market opportunities of cancer drugs through independent discovery and external authorization to introduce innovative products. With the Company's own products and advantages in clinical development, the Company has been efficiently, positively and reasonably attracting, exploring and carrying out potential global business cooperation opportunities in an open-minded attitude and ultimately achieved the common goal of win-win cooperation by complementing the advantages of partners. In 2022, the Company actively participated in corporate academic exchange activities, such as DIA International Case Seminar on Drug Registration - Clinical Development and Registration Strategy Discussion, Cancer Black Technology Dialogue, the 2nd DJSeedin Innovation Partnering Conference, and the global clinical development online series of salons to consider clinical plans, operations, and registration strategies, to share its latest study concepts and results with the same industry, thus actively promoting industry cooperation and forming complementary advantages.

At the same time, the Company has established strategic and business cooperation with a number of global leading companies through diversified cooperation methods such as joint development, strategic cooperation, product introduction, contract cooperation, etc. Guided by the patient needs, the Company will focus on the world's cutting-edge cancer treatment technology and continue to build an ecosystem of chronic cancer treatment and a highly collaborative innovative drug pipeline with leading product development capabilities and experienced management team to provide more treatment options for patients around the world.

Continuously increased R&D investment

As of December 31, 2022
R&D investment RMB

350 million yuan

Account for total revenue

61.78 %

As an innovative drug company led by R&D, R&D investment is the premise for expanding R&D capabilities. As of December 31, 2022, the Company invested RMB 350 million in R&D, accounting for 61.78% of the total revenue.

Through continuously increased investment in R&D, 3D Medicines has strengthened its competitive advantage in drug discovery, development and commercialization of innovative cancer treatments. In addition, 3D Medicines has continued to optimize and strengthen the drug development platform, integrated top-end and cutting-edge technologies, efficiently screened and designed differentiated innovative molecules, and timely carried out intellectual property protection. What is more, 3D Medicines has adopted innovative clinical trial design and carefully deployed clinical strategies to constantly expand new indications of product under study, provide better treatment options for patients, support commercialization and continue to explore overseas market development to achieve the international layout of products. The manufacturing system and facilities for the drug development process are also being built in accordance with cGMP standards to support the production and commercialization of candidate products.

Innovative R&D results

Technology platform innovation

The Company attaches great importance to the construction of R&D technology platforms because it believes that R&D is crucial for maintain industry competitiveness. Building a perfect R&D technology platform can make the Company's R&D work systematic and programmatic; standard operating procedures and sound platform systems will reduce unnecessary R&D costs and provide an effective and broad development base for drug molecular screening, thereby increasing the speed of development and the likelihood of success.

The Company has established a platform that enables it to conduct R&D in the field of chronic cancer treatment. Relying on the Company's proprietary R&D platform, the Company can carry out preclinical R&D activities, including drug activity screening, drug cell function study, drug biochemical study and biomolecule detection.

The Company's R&D platform has strong molecular screening and design capabilities to improve the success rate of molecules from preclinical study to market, achieve innovative therapeutics and support pipeline assets built around key pathways and targets. The Company's R&D centers in Shanghai and Beijing include large and small molecule platforms, cell line screening platforms, and compound screening platforms. The Company's R&D centers also support drug activity screening platform, drug cell function study platform, drug biochemical study platform and biomolecular detection platform, which can conduct experimental study on common molecular and cell biology, such as cell viability detection, ELISA, real-time PCR, western blotting, molecular cloning, biochemical enzymes and flow cytometry.

At the same time, the Company has hundreds of commercial cancer cell lines from ATCC, ECACC, JCRB and RIKEN, the world's four largest cell banks. The source of cell cancer covers cancer types with high prevalence in the United States, Europe and Asia, such as lung cancer, liver cancer, colon cancer, stomach cancer, esophageal cancer and breast cancer, which can provide a broader, more effective and more convenient screening of candidate drugs in early preclinical R&D, and these samples also show significant advantages in the development of cancer biomarkers.

The Company is currently working with XtalPi and it plans to further cooperate with other third parties to further integrate AI-enabled digital drug R&D infrastructure to facilitate drug development and improve efficiency. The Company also continue to further strengthen its R&D capabilities with the experience accumulated when cooperating with renowned partners.

Important R&D progress

Starting from the perspective of clinical needs, the Company has created a number of innovative candidate drug pipelines with differentiated characteristics and synergistic mechanisms by using advanced technology platforms, experienced teams, forward-looking international drug candidate cooperation and efficient clinical development capabilities. As of December 31, 2022, the Company has progressed the R&D projects smoothly even if the international pandemic is complex and changeable, and several product pipelines have made significant progress.

Envafolimab® (subcutaneous PD-L1) performed well in the first year of launch for its first indication, and progressed smoothly in trials of other indications under study.

As the Company's first marketed product, Envafolimab® (Envafolimab Injection), the world's first subcutaneously injected programmed cell death-ligand 1 (PD-L1) inhibitor, was approved in China in November 2021.

Envafolimab® is the world's first and currently the only subcutaneous PD-L1 inhibitor approved for marketing. At present, PD-1/PD-L1 treatment in the global market requires frequent intravenous drip. However, patients can complete the administration within 30s through subcutaneous injection after Envafolimab® is marketed, solving the unmet clinical needs of patients with venous intolerance, giving patients more treatment options and greatly shortening the administration time, thereby better improving the quality of life of patients.

In addition to better convenience and compliance, Envafolimab® has been recognized by professional associations in the first year of its marketing, including 6 being incorporated into CSCO diagnosis and treatment guidelines and 1 into the treatment guidelines of the China Anti-cancer Association.

Envafolimab® (subcutaneous PD-L1) has also been recognized by the market and patients in the first year of its marketing in ensuring the effect, while bringing a convenient and rapid treatment process to patients, reducing the psychological and physiological burden of patients, and largely solving the clinical difficulties of out-of-hospital drugs. As of December 31, 2022, the annual sales of Envafolimab® reached RMB 567 million.

In addition to market recognition, the Company is accelerating clinical development for other indications of Envafolimab® and has made several significant progresses this year. First of all, guided by the patient needs, Envafolimab® (subcutaneous PD-L1) was approved of "a dose of 300mg every two weeks". The approval of the new dosage will greatly reduce the frequency of drug use, further improving the convenience of drug use for patients, and giving cancer patients better treatment options.



In addition, other clinical trials of Envafolimab® are progressing well, and in September 2022, the clinical trial of the combination therapy of Envafolimab® with Erbitux® was approved by IND. In December 2022, an IND from the FDA was obtained for Envafolimab® (subcutaneous PD-L1) to conduct the Phase II clinical trial in the treatment of advanced solid tumors of dMMR, taking another solid step towards the overseas development of the drug. At the same time, as of 2022, Envafolimab® has published 4 clinical data results, including:

- Data update and subgroup analysis of subjects with advanced solid tumors of MSI-H/dMMR treated with Envafolimab® (subcutaneous PD-L1) after a follow-up of 26.8 months.
- Results (announced at the CSCO Conference) of three Phase I clinical trials of Envafolimab® (the world's first subcutaneous PD-L1) conducted in China, the United States, and Japan for the treatment of patients with advanced refractory solid tumors.
- Results of the Phase II clinical study of Envafolimab® (subcutaneous PD-L1) combined with FOLFOX, first published online in the Chinese Journal of New Drugs in Volume 31, Issue 13, 2022.
- Trial results of Envafolimab® (subcutaneous PD-L1) for Phase I clinical trials of advanced solid tumors conducted in Japan.

Significant progress in other core product pipelines

During the reporting period, the Company also made outstanding progress in a number of core products, including the GAS6/AXL inhibitor Batiraxcept (3D229), which has been under global multi-center clinical phase III trial (MRCT), and the tumor vaccine 3D189 (Galinpepimut-S (GPS), targeting Wilms tumor 1 (WT1) protein, which is present and overexpressed in a series of hematological malignancies and solid tumors. The Company has enrolled the first patient in the Phase I clinical trial for hematological malignancies.

Cancer vaccine 3D189 (Galinpimut S, (GPS)) 2022 timeline:

In April 2022, 3D189 was approved for clinical trials in patients with acute leukemia who are WT1 positive and are in complete remission after completing at least first-line standard therapy, and patients with multiple myeloma, non-Hodgkin lymphoma or myelodysplastic syndrome in the higher-risk group who achieve complete response or have an optimal response to partial response.

In October 2022, the first patient was administered during the Phase I clinical trial of 3D189 in China. 3D189 was for patients with acute leukemia who were positive for Wilms tumor gene-1 (WT1) and were in complete remission after completing at least first-line standard therapy, and patients with multiple myeloma, non-Hodgkin lymphoma or high-risk group myelodysplastic syndrome who achieved complete remission or the optimal response was partial remission.

In October 2022, the clinical approval of 3D189 API was completed for localized production.

Batiraxcept (3D229) 2022 timeline:

Phase III clinical trial was launched in China in February 2022. As of September 30, 2022, eight patients in China have been enrolled in this MRCT.

In April 2022, IND approval for Phase Ib/II clinical trials in NSCLC, RCC and UC patients was obtained.

In September 2022, the Phase I clinical study of Anexelekto (AXL) inhibitor 3D229 (AVB-500, Batiraxcept) for bridging purposes in healthy subjects in China was completed and the conclusions were released at the CSCO Conference.

On December 19, 2022, 3D229 CMC changed sIND with approval from CDE, and after this approval, 3D229 samples produced by the new process can be used for clinical study.

R&D and production base construction

The Company is striving to improve its own R&D and production capacity, and actively build an industrial model integrating study and production.

The Company is constructing internal production facilities in Xuzhou City, Jiangsu Province. The manufacturing system and facilities for the entire drug development process (including chemical and biological agents) comply with current good manufacturing practices (cGMP) and meet strict global standards. To prepare for the large demand for drugs after commercialization, we have purchased land use rights with a total area of 65,637.97m^2 in Xuzhou. The Company has obtained a construction permit and started constructing new production facilities in Xuzhou City.

The Company has purchased land located in Xuzhou, with a total usable area of

65,637.97 square meters

Conceptual drawing of new production facilities

Conceptual drawing of new production facilities

Drug accessibility

Hoping to make every patient have access to drugs that are at the forefront of the world and meet different clinical needs, the Company always believes that drug R&D shall develop drugs that meet the patient needs and are easily accessible from the perspective of the accessibility of drugs.

Therefore, the Company improves the accessibility of its products in terms of continuous discovery of clinical needs, acceleration of clinical trials and drug marketing, expansion of drug sales channels, etc., striving to benefit the public.



In terms of the discovery that does not meet clinical needs, the Company always pays attention to the academic development in the field of cancer, analyzes the unmet clinical needs in the field, and actively communicates with scientific consultants, top domestic scholars and experts to understand the urgent problems to be solved in clinical practice. For the treatment of PD-(L)1 resistant patients, the Company has carried out a series of exploratory clinical trials for PD-L1 combination to give these patients without treatment options new treatment options.

The Company also actively introduces new foreign mechanistic therapeutic drugs, such as joining the international multi-center clinical trial developed globally by Batiraxcept (3D229), so that Chinese patients with advanced platinum-resistant relapsed ovaries can receive the most innovative drugs simultaneously with global patients. The Company also launched the Phase I clinical study of the cancer vaccine 3D189 (Galinpepimut-S (GPS)) in patients with hematological tumors, so that Chinese patients with acute myeloid leukemia who are unable to undergo hematopoietic stem cell transplantation can continue to remission from the cancer vaccine treatment.

The Company will also continue to focus on cancer patients accounting for a small amount, such as MSI-H/dMMR and TMB-H patients, so that patients with rare cancers can also have better treatment.



In 2022, the Envafolimab Injection was sold around

Province in China

30

City and commercially

200+

Hospital

1,000+

Pharmacie

1,000+

In terms of clinical trials and drug marketing, we start and operate clinical trials efficiently in the order of priority, and establish a project group management system for the trials. All departments collaborate at the project group level to reduce communication costs and improve efficiency, and the project group supervises the execution of the trials and report regularly to ensure the quality and progress of the trials.

Meanwhile, we actively build our drug sales network. In 2022, our first commercial product, Envafolimab® (subcutaneous injection PD-L1), was available in 1,000 hospitals and 1,000 pharmacies in more than 200 cities in 30 provinces of China, and was listed in the people-benefit insurance (urban customized commercial medical insurance) in 17 cities, including Wuxi, Changzhou, Nanjing, Suzhou, Yancheng, Yantai, Jining, Qingdao, Hebei, Shanxi, Ningbo, Xiamen, Fujian, making more and more patients afford our drugs, thus reducing social pressure, and improving the quality of life.

PRODUCT LIABILITY

In 2022, the Group didn’t have any quality accidents or any product recall events caused by quality problems.
We organized 9 quality training sessions for 141 trainees.
The Company had 171 suppliers.
The risk events of supply chain were 0.

Quality training session	Traineer
9	141

Supplier	Risk event of supply chain
171	0

PRODUCT LIABILITY

Quality management

Since product quality and safety is the core embodiment of corporate value, the Company strictly abides by the applicable laws, regulations and regulations such as the Drug Administration Law of the People's Republic of China and the Good Manufacturing Practice of Medical Products in the pharmaceutical production. In order to guarantee product quality and safety, our Quality Assurance (QA) and Quality Control (QC) departments have established a sound quality management system and supervised the quality and risks of drugs throughout the life cycle.

As of December 31, 2022, our QA and QC team had 7 employees in total. Main responsibilities of QA and QC departments include: (i) establish drug quality management system documents and comply with the requirements of Good Manufacturing Practice (GMP); (ii) conduct regular audit of the quality management system of the entrusted drug manufacturers and supervise their continuous quality assurance and control capabilities; (iii) review batch records, approve and release the products. By 2022, we conducted in-house review for many times and quickly corrected all issues identified.

Quality management mode

Quality control and assurance	Actions and measures	Role and significance
QAS (quality assurance system)	Establish the system based on GMP, all organized and planned activities to ensure that the pharmaceutical quality conforms to the intended use.	All organized and planned activities to ensure that the pharmaceutical quality conforms to the intended use.
Documents about the quality management system	The Company has set up MAH-related management document procedures to guide the holder to carry out quality management throughout the life cycle.	Guide the holder to carry out quality management throughout the life cycle.
Comprehensive quality training	Nine quality training sessions, mainly in the form of PPT face-to-face teaching, with 141 participants.	Get familiar with the position responsibilities and knowledge.
Quality supervision and audit	Carry out comprehensive supervision and audit of the quality system at least once a year, with the audit scope and field: compliance of MAH quality management system with GMP, including quality management, organization and personnel, document and record management, and enact and take corrective measures for the defects identified .	Ensure that the Company's production quality management activities can comply with GMP requirements, and achieve continuous improvement.
Core personnel of quality assurance	In order to ensure the adequacy and effectiveness of the quality system, the core quality assurance personnel of the Company, such as the responsible person, quality director, qualified person, and manufacture head, all have relevant professional background and many years of GMP management experience, and can fully coordinate and mobilize relevant resources to carry out quality management activities, and all departments carry out various work in accordance with the established management procedures.	Ensure that the Company can conform to the requirements of the relevant laws and regulations.

Production and safety

We strictly abide by the Drug Administration Law of the People's Republic of China, Regulations for Implementation of the Drug Administration Law of the People's Republic of China, Measures for The Administration of Drug Registration and other relevant laws, regulations and provisions, and carry out research and manufacture of investigational new drugs in accordance with the Good Manufacturing Practice of Medical Products (GMP), Good Clinical Practice (GCP) and Good Laboratory Practice for Non-clinical Laboratory Studies (GLP).

Production safety

The Company entrusts manufacturers for commercial production of its products. In 2022, the Company had no working days lost due to employee injuries in production and operation positions.

Management of non-compliant products

Responsible for patients, providing high-quality and safe products is the goal of our quality control work. We have established the Standard Management Procedures for Non-compliant Products to effectively manage non-compliant products.

Supply chain management

We abide by the Government Procurement Law of The People's Republic of China, the Law of the People's Republic of China on Bid Invitation and Bidding and other relevant laws and regulations. Meanwhile, the Company has formulated management documents such as Procurement Management System, Service Provider Evaluation Form and New Supplier Information Form to continuously optimize the supplier management system. The Company adheres to the procurement mode of compliance, transparency and diversification, and actively communicates and cooperates with suppliers. We are establishing a reliable and competitive supply chain guarantee system with our suppliers.

By the end of 2022, the Company had a total of 171 suppliers, mainly distributed in Shanghai and Beijing.

Number and distribution of suppliers



In 2022
Supply chain risk event

0

The Purchasing Department internally evaluated and audited supplier

82

In 2022, the Company optimized and improved the procurement management system, contributing to more efficient management of the supply chain. Prior to the selection of suppliers, we will audit the qualifications of suppliers, fully consider the relevant impact of suppliers on the environment and society, incorporate the audit scoring mechanism, and conduct on-site inspection and audit as appropriate. The suppliers after qualification will be included in our supplier database.

We implement annual audit system for suppliers, auditing their product and service quality, brand value, price, communication mechanism, flexibility, and order response speed. We eliminate the suppliers with low scores, so as to ensure the quality of suppliers and reduce the risk of suppliers. In 2022, there were no supply chain risk events according to statistics. In 2022, the purchasing department conducted an in-house evaluation and audit of 82 suppliers.

Excellent after-sales service

In accordance with the relevant national laws and regulations, the Company has revised the Standard Management Procedures for Returns, and clearly stipulated the returns of the Company.

Return process: The dealers provide the reason for the return application and the proof of the return application. After the approval of the return application by the QC head, the products will be transported by cold chain (2-8°C) to the entrusted manufacture. The entrusted manufacture verifies the returned products and places in the return area for isolated storage, and fills in the relevant records of the returns. After the quality is proved to be not affected upon testing, inspection and investigation, and subject to the evaluation by the quality management department according to the operation procedures, the returns can be repackaged and reshipped for sale. The returns which are judged to be unqualified, or fail to meet the storage and transportation requirements, are destroyed under the supervision of QC department.



Abnormal events and product recall

The Company has organized personnel from the quality management department to investigate and evaluate the events and discuss plans and measures according to the Administrative Measures for Drug Recall and the Standard Management Procedures for Drug Recall (handling system and scheme). In 2022, the Group had no quality accidents and no product recalls due to quality problems.

Recall process: Formulate the recall plan and initiate recall after determining recall upon the assessment of drug safety hazards, issue the recall notice to the drug handling and use organizations, and record the recall plan, recall notice and potential quality safety hazards and report to the provincial drug administration within the prescribed time limit; store the recalled drugs separately, track the recall progress, and report to the provincial drug administration; and handle the recalled drugs under the supervision of relevant departments, summarize the whole recall process, and report the recall and handling situation to the local provincial drug administration and healthcare authority within the prescribed time limit, and close the recall and archive all data if there are no problems in all aspects.



RESPONSIBLE OPERATION

In 2022, the Group had no information leakage event.

The Company did not involve any corruption cases.

The Company didn’t receive any anti-fraud complaints.

The Quality Management Department organized two training sessions and invited colleagues of the Legal and Compliance Department as lecturers.

Information leakage event	Corruption case	Relevant training session
0	0	2

RESPONSIBLE OPERATION

Responsible marketing

The Company carries out marketing and promotion work in an honest and responsible manner. Regarding drug marketing, the Company strictly follows the relevant laws and regulations and industry standards such as the Drug Administration Law of the People's Republic of China, the Pharmacopeia of the People's Republic of China, the Regulations for Implementation of the Drug Administration Law of the People's Republic of China, the Regulations for the Management of Drug Instructions and Labels to manage the use of drug labels and compliance sales, and the Company ensures that the drug packaging is in line with national and industry standards through the in-house system construction, such as the Standard Management Procedures for OEM on Drugs, the Standard Management Procedures for Commission Sales of Drugs, and the Standard Management Procedures for Drug Marketing Release and other system files.

The Company is undertaking the commercial operation of Envafolimab® in Chinese mainland through the cooperation with third parties. As required by the Company according to the same standards, the partners shall strictly abide by all relevant laws, regulations and provisions , such as the Drug Administration Law and the Standards for the Examination and Publication of Drug Advertisements in all activities involved in commercial operation, use comprehensive, accurate and reasonably-based promotional materials in the promotion process, and avoid any false or illegal publicity behaviors. We resolutely put an end to any deceptive, false or misleading information transmission, and firmly take the life safety and health of patients as the first priority.

We abide by the Anti Unfair Competition Law of the People's Republic of China, Interim Provisions on Prohibition of Commercial Bribery and other relevant laws, regulations and policies, and establish the Sales Management System, Regulations on Product Sales Management , Regulations on Product Complaint Management and other quality system regulations to ensure that all sales activities are in line with the principle of full legality.

Customer rights and interests

Consumer data and privacy

According to the "Tripartite Agreement of KN035 Cooperation", product promotion is not our responsibility, so consumer data and privacy issues are not involved for the time being. Nevertheless, we have been placing customer satisfaction as the core of our services, and unswervingly protecting the rights and interests of consumers.



We comply with the laws related to the protection of consumer data and privacy in China, such as the Law of the People's Republic of China on Protection of Consumer Rights and Interests, the Personal Information Protection Law of the People's Republic of China, and the Information Security Technology - Personal Information Security Specification.

We are gradually developing the company system related to consumer data and privacy protection, so as to ensure that employees can understand and comply with the relevant policies of the Company.

Complaint handling

Pharmaceutical products, as a kind of special commodity, are associated with the health and life safety of patients. Maintaining the health of patients and providing a strong management guarantee system is not only the social responsibility of an enterprise, but also an important cornerstone for the good and orderly development of an enterprise.

The Company and its entrusted manufacturers have been adhering to strict and standardized procedures for handling drug complaints, including the Standard Management Procedures for Handling User Complaints of QC Department, the Management of Product Complaints of the Pharmacovigilance Department and other system documents, and constantly improving the working mechanism for handling drug complaints, so as to make clear provisions and effective supervision on the process of receiving and sending registration, disposal time limit, related procedures and undertaking departments of drug complaints.

Meanwhile, we also make much account of the qualifications of relevant personnel, as well as the rigor and accuracy of product complaint response content, and constantly strengthen the training of the staff who accept and handle complaints on drug regulatory laws and regulations, drug safety characteristics and other professional knowledge, so as to improve the ability and professional level in handling complaints. More importantly, we attach great importance to the privacy protection of patients and reporters. All product data collection and processing systems are professionally encrypted, which can strictly protect the relevant information of patients and reporters in each link.

On the basis of the systems and code requirements above, the Company has registered for a national 400 free hot line, provided 24-hour pharmacovigilance hot line, and regular training for the Company and all entrusted manufacturers, so as to ensure that no complaints and inquiries related to doctors and patients are missed, and each product complaint and inquiry can be handled professionally and promptly. There is a specially-assigned person responsible for each case, and each department needs to keep all records of all handling processes. According to the enterprise production quality and operation quality standards and local requirements, it is necessary to conduct quality inspection on the samples provided by patients or reporters promptly, and give a quality inspection conclusion. Any potential safety risk identified in the process of product complaint shall be immediately reported to the safety management committee of the Company, and then managed according to the Regulations of Safety Management Committee. If there are any cases and individuals in violation of the systems and requirements above, it is necessary to conduct an investigation, find the root causes, and take corrective and preventive measures. The Company has received 10 cases of product-related complaints, all of which have been handled properly according to relevant national requirements and company specifications.

Business ethics

Compliance and anti-fraud management

We always pursue integrity and ethical business conduct, and stand firm against commercial bribery, money laundering, corruption and embezzlement in any forms. Our employees are required to abide by the laws and adhere to the criteria of integrity and ethics in the daily business.



The Company strictly complies with the requirements of laws, regulations and other regulations, such as the Anti Unfair Competition Law of the People's Republic of China, the Interim Provisions on Prohibition of Commercial Bribery, and the Law of the People's Republic of China on Anti-money Laundering. The Company has established the Measures for Management of Whistle-blowing and Handling Improper Conduct, the Management Rules for Communication with Government Officials, Medical and Health Professionals and Medical and Health Professional Institutions and Speakers, the Policy for Conferences and Activities, the Anti-commercial Bribery Management System, the Anti-money Laundering Management System, and the Third Party Due Diligence Management System to define the ethical standards of the Company and the compliance requirements to be followed. Moreover, the Company has also carried out in-house audit, risk assessment and other work to timely find the vulnerability in compliance management, and constantly reform and optimize the compliance system. The Company had no corruption litigation cases this year.

Complaining and whistle-blowing ways

We have introduced the Management Measures for Whistle-blowing and Handling Improper Conduct (regulations for reporting procedures), and registered for a whistle-blowing E-mail (compliance@3D-medicines.com), and we encouraged employees to whistle-blow and complain about compliance and fraud to the Company, and protected the interests and privacy of whistleblowers to the greatest extent to ensure the fair and equitable treatment for them. Regarding any whistle-blowing and complaining information that need to be investigated upon preliminary confirmation, the legal and compliance department would organize, and jointly establish employee integrity files with the human resources department, and then launch an investigation after authorized by the CEO, and report and fed back the results to the Company's management.

In 2022, the Company did not receive any anti-fraud related whistle-blowing information.

Training on combating corruption and upholding integrity as well as internal control risks

The Company organizes employees to participate in anti-corruption and compliance training every year to improve the compliance awareness of all employees. In 2022, the Quality Management Department organized colleagues in the Legal & Compliance Department as the trainers to provide 2 training sessions. Multiple aspects are involved in the publicizing and implementation, and training of the relevant anti-commercial bribery systems of 3D Medicines, such as anti-commercial bribery management system, anti-money laundering management system, third party due diligence management system, misconduct whistle-blowing and handling management measures, and meeting and activity policies. All employees of the Company actively participate in learning the relevant systems of anti-commercial bribery, and correctly comply with the relevant laws and regulations of anti-commercial bribery, thus better maintaining the image of the Company and fundamentally promoting the upward development of the Company.

Risk control

Internal control management

Starting from the enterprise risk and combining with its own development situation, the Company has established a corporate legal person management system in accordance with the requirements of establishing a modern enterprise system, and set up an organization that meets the Company's business scale and operation management needs, and continuously improved and optimized the Company's internal control management system from the five aspects of control environment, risk assessment, control activities, information and communication and internal supervision, so as to ensure that the internal control system is effective and sound, and the responsibilities are clear.

Attaching great importance to the construction of internal control management system, the Company has formulated a series of company policies and processes involving sales, procurement, quality management, pharmacovigilance, legal and compliance, finance, internal audit, human resources, and IT. During the reporting period, in order to improve the risk and internal control awareness of management and employees, the Company provides online and offline publicity and implementation training for employees.

Risk control

The Company believes that a sound risk management system will contribute to its sustainable development. We attach great importance to the risks of all production and operation links of the Company, especially the major risks related to corporate strategy, purchase and sale of major assets, foreign investment and related-party transactions.

Led by the board of directors, the Company's risk management system mainly consists of Legal & Compliance Department, Internal Control and Audit Department, and business departments and business teams.

Relevant project approval meetings will be held for major risks, in which the members of Board of Directors, legal & compliance department, internal audit and related business departments will participate to jointly identify risk issues and consider potential risks and opportunities of the overall project, and the Board of Directors will give approval and make final decision after repeated deliberation and review.

Data security and privacy protection

The operation and management of the Group is based on the strict compliance with relevant laws and regulations, such as the Cyber Security Law of the People's Republic of China, the Data Security Law of the People's Republic of China, the Biosafety Law of the People's Republic of China, and the Anti Unfair Competition Law of the People's Republic of China. Meanwhile, the Company has also taken the following measures to protect the data security and privacy data from infringement.

Cyber Security

The latest mainstream next-generation firewall is used in all internal network exits of the Group, which is provided with security policy, intrusion prevention, Trojan virus detection, and data leakage prevention.

Data safety

The Group has formulated the SOP for Computer Information Management, the SOP for Business Continuity, Data Disaster Recovery and Emergency Response and the SOP for Electronic Document Management, and carried out data safety storage and archiving according to these SOPs. Remote three-copy disaster recovery management is also performed for important business data.

E-mail

Microsoft Exchange mail system and GDPR-compliant Malistore mail archive system are used.

In 2022, the Group had no information leakage events.

PEOPLE FIRST

In 2022, the number of working days lost of the Company due to work-related injuries was zero, and the number of deaths due to work-related injuries was zero.
In 2022, the Company had no labor and employment-related violations or disputes.
The Group had a total of 245 regular employees, 64% of whom were females.
A total of 11 training sessions for all employees were organized by the Quality Management Department for a total of more than 1,600 trainees, with an average training length of 1 to 1.5 hours per session.

Working day lost due to work-related injury

0

Death due to work-related injury

0

Regular employee

245

Female

64%

Training sessions for all employee

11

Training length on average

1 - 1.5 hours

Trainee

1,600+

PEOPLE FIRST

Talents are valuable assets of our company, and constitute the driving force for our long-term steady development. The Company is committed to providing employees with a healthy, safe and comfortable working environment, as well as a harmonious and friendly, fair and just employment relationship. The Company focuses on employee growth and career development, such as providing professional training and open development channels for employees, and continuously increasing the construction of various functional talent echelons from source innovation, clinical development to commercialization.

Legal employment

Strictly abiding by the Labor Law of the People's Republic of China, Labor Contract Law of the People's Republic of China, Social Insurance Law of the People's Republic of China and other relevant laws and regulations, the Company has established legal employment relations with employees, and paid social insurance and housing accumulation funds for employees in accordance with national and local regulations, guaranteeing the legitimate rights and interests of employees.

We abide by the Law of the People's Republic of China on the Guarantee of the Rights and Interests of Women, the Provisions on the Prohibition of Using Child Labor, the Trade Union Law of the People's Republic of China and other laws and regulations, protecting the rights and interests of female employees, not employing child labor, and opposing forced labor.

Respecting for human rights, and opposing workplace harassment, bullying and intimidation, our company has specially established relevant provisions in the Recruitment Management System, Employee Handbook and other documents to provide protection for employees.

The Company provides employees with good salary and welfare. We have formulated regulations, such as Management Measures for Employee Salary and Management Measures for Employee Welfare to standardize the management of salary and welfare. Employee salary consists of basic wage, various allowances and variable bonuses. The Company has proposed a long-term incentive plan to implement equity incentives for qualified employees.

The Company is committed to employment equity, ensuring that employees are not discriminated in the recruitment and work on the basis of race, religion, gender or other factors. As at December 31, 2022, the Group had a total of 245 permanent employees, including 64% females.

As of December 31, 2022
permanent employee

245

Female

64%

Employment diversity and equity

Composition of employees



Gender	Male	Female
Quantity	88	157
Proportion	36%	64%



Age	<30	30-50	>50
Quantity	69	172	4
Proportion	28%	70%	2%



Resident work area	Chinese Mainland	Outside Chinese Mainland
Quantity	243	2
Proportion	99%	1%

Employee turnover statement

Gender	Male	Female	Total
Quantity	14	21	35
Proportion	5.0%	7.5%	12.5

Age	<30	30-50	＞50
Quantity	14	20	1
Proportion	5.0%	7.1%	0.4%

Resident work area	Chinese Mainland	Outside Chinese Mainland
Quantity	34	1
Proportion	12.1%	0.4%

Health and safety

The Company attaches great importance to the protection of employees' health and safety in daily management, strictly abides by the Production Safety Law of the People's Republic of China and other laws and regulations, and formulates a series of management regulations, such as Laboratory Safety Manual, Innovative Drug R&D Laboratory Safety Manual, and the Management System for Precursor Drugs, striving to create a healthy and safe working environment for employees.

The Company strictly abides by the Law of the Peoples Republic of China on Prevention and Control of Occupational Diseases and other relevant laws and regulations to protect the occupational health of employees. The Company guarantees the safety and health of employees by providing annual health check-ups, labor protection supplies, medical boxes and other measures. During the outbreak of COVID-19, the Company not only set up daily monitoring including temperature registration and health punch, but also provided flexible home office support and attendance management for employees involved in the outbreak of COVID-19 according to the actual situation, and paid salaries normally. In addition, we also provided material assistance and psychological counseling for colleagues in areas seriously affected by the outbreak of COVID-19. Regarding the working environment, in addition to the provision of basic fire equipment, the Company carried out formaldehyde and other harmful substances detection and passed the tests. We installed facilities and equipment in the production environment, conducted hazardous substances testing, equipped emergency supplies, and timely checked and replaced defective equipment. In 2022, the Company lost 0 working days due to work-related injuries and 0 deaths due to work-related injuries.

In 2022

Working day lost due to work-related injury

0

Death due to work-related injury

0

Democratic communication

Smooth democratic communication can help the Company understand the problems encountered by employees in workplace faster, and timely solutions can help improve work efficiency and contribute to the development of the Company. We hope that employees have the full right of expression and participation, and everyone can be a builder and engineer of the Company.

We try to understand their feelings and expectations through new employee seminars; The 3DM Dialogue we implemented is not only a periodical performance communication channel, but also a window to listen to the opinions and suggestions of employees at all levels. We invite employees to participate in the product naming of the Company's investigational drugs and reward active participants and contributors. We implement publicity prior to appointment of middle and senior management personnel, so as to make them subject to the supervision of all employees.

In 2022, 3D Med had no violations or disputes related to labor employment.

We will also continue to be committed to the construction of a more effective democratic communication platform, providing support for employees to express their opinions and contribute their wisdom.

In 2022, the Company had no violations or disputes related to labor employment.

Employee remuneration and benefits

We are committed to establishing an effective compensation system and providing competitive compensation and benefits. The Company has formulated the Management Measures for Employee Remuneration and the Performance Management Standards. The salary adjustment, bonus and promotion of employees are all related to their work-related results.

The Company has formulated the Management Measures for Employee Remuneration to standardize and safeguard the benefits of employees. In addition to statutory benefits, the Company provides supplementary benefits for employees, such as allowance subsidies (transportation subsidies, lunch subsidies, communication subsidies), paid sick leave, annual physical examination, department team building fund, continuing education incentives, holiday gifts, and consolation money.

Employee promotion

The Company is committed to providing fair opportunities of promotion. The Company has formulated the Management Measures for Promotion, involving the professional conduct, work performance and comprehensive ability as well as the years of working of employees in the Company.

Care to employees

A relaxed and pleasant working environment can help employees better adapt to the workplace, thus improving work efficiency, and better facing more challenges. The Company always advocates the protection of the daily quality of life of employees.

The Company holds team building activities on an irregular basis, including group trips, team dinners, and party to enhance collective friendship; and the Company organizes the activity of "walking with vigorous strides", and encourages and rewards employees' participation in the form of team competition. During the outbreak of COVID-19, the Company urged employees to do physical exercise and build a strong body in the form of "Online Sports Meeting".

The Company has purchased table tennis tables, set up badminton court, and bought fitness equipment to support employees' physical fitness activities. In addition, we also organize lucky draw in the company annual meeting, and distribute gifts to employees in festivals. We provide employees with a certain number of paid sick days; we offer condolence money to sick employees and employees with deceased relatives; and we develop a "Watch Plan" to provide certain cost subsidies to employees or their relatives with tumors when they purchase tumor gene sequencing testing services. Adhering to the "people-oriented" concept, we provide help to employees as we can.

- Group tour
- Team dinner
- Get-together
- Walking exercise
- Online sports meet

ADHERE TO THE CONCEPT OF "PEOPLE-ORIENTED"

Employee training and development

Employees are the core asset of our company, and the ability of employees determines the value of assets. Therefore, we attach great importance to the training and promotion of employee knowledge, skills and occupational quality. We have established a complete training system to improve their technical level, professional knowledge and occupational quality of employees, and established more promising career development space and opportunities for employees.

Our training includes the following categories: new employee induction training, vocational training, professional knowledge training. Training contents (including but not limited to): training of company management system, quality system training (including but not limited to GCP, GMP, GLP training), compliance training, safety training, pharmacovigilance training, and special training in various professional and technical fields. Training is organized and implemented by HR Department, Legal & Compliance Department, and various business units separately or jointly according to their responsibility areas.

We have formulated the Management Measures for Employee Continuing Education Incentive to encourage and support employees to continue learning, and constantly improve the professional knowledge level and overall professional quality, so as to better meet the needs of the Company's long-term development and employees' personal career development.

In 2022

Training sessions for all employee

11

Training length on average

1 - 1.5 hours

Trainee

1,600+

Provided for female employee

1,024 hours

Provided for male employee

576 hours

Employee training: New employee onboarding; Vocational training; Training on post

In 2022, the Quality Management Department organized and carried out a total of 11 training sessions for all employees, including the vocational training covering market, laws, R&D, quality control and other aspects, with the average training duration of 1-1.5 hours, and the person-times of employees involved in the training more than 1,600. The total training duration for female employees was about 1,024 hours, and that for male employees was about 576 hours.



PUBLIC WELFARE

In 2022, the Company's charitable contributions totaled RMB 53.3 million. The Company established the "3DMed Education Charity Fund" and distributed RMB 400,000 in donations to 20 poverty-stricken students.
3DMed donated Envafolimab for the patient aid project, covering 30 provinces and 269 cities and benefitting 20,000 patients.

Charitable donation of the Company in 2022

RMB

53.3 million yuan

Donations to 20 poverty-stricken students RMB

400,000 yuan

PUBLIC WELFARE

The Company always adheres to fulfilling social responsibility, and actively participates in social welfare undertakes; in addition, it also focuses on the key areas of social responsibility while focusing on patients, and actively organizes various forms of volunteer activities.

Charitable donation to students

In terms of education construction support, the Company established the "3D Medicines Love Education Fund" and distributed the first batch of donations to 20 poor students in 2022, totaling RMB 400,000.


04 · 综合 金沁湖快报 2022年3月11日 星期五

馨香一瞬

博士播大爱 真情暖学子

"思路迪医药爱心助学基金"捐赠贫困学生40万元

Charitable donation of the Company in 2022

RMB

53.3 million yuan

Donations to 20 poor students RMB

400,000 yuan

Charitable donation of medicine

In order to reduce patients' economic burden arising from continuous treatment of cancer, help more tumor patients receive standardized and continuous immune therapy, and prolong their life expectancy and improve their quality of life, we provided targeted fundraising support to Beijing Kangmeng Charity Foundation, and provided tumor patients with free drugs (Envafolimab) to aid their treatment.

In 2022, 3D Medicines donated Envafolimab in patient assistance projects, covering more than 20,000 patients in 269 cities in 30 provinces.

In 2022
3D Medicines donated Envafolimab Injection to patient assistance programs.
Covered province

30

City

269

Benefit patient

20,000+

"In order to reduce patients' economic burden arising from continuous treatment of cancer, help more tumor patients receive standardized and continuous immune therapy, and prolong their life expectancy and improve their quality of life, we provided targeted fundraising support to Beijing Kangmeng Charity Foundation, and provided tumor patients with free drugs (Envafolimab) to aid their treatment."

LOW-CARBON ENVIRONMENTAL PROTECTION AND GREEN DEVELOPMENT

In 2022, the Company didn't find any major environmental protection issues or environmental penalties.

Greenhouse gas emission 0.07t CO_2e/RMB 10,000 of revue

Energy consumption 20.00kWh/RMB 10,000 of revenue

Water consumption 0.19m³/RMB 10,000 of revenue

Greenhouse gas emission

0.07 t CO_2e/RMB 10,000 of revenue

Energy consumption

20.00 kWh/RMB 10,000 of revenue

Water consumption

0.19 m³/RMB 10,000 of revenue

LOW-CARBON ENVIRONMENTAL PROTECTION AND GREEN DEVELOPMENT

Environment management system

Adhering to the concept of green development, 3D Medicines continues to strengthen environment management and pollution control, fully considers the impact of enterprise operation and production on the environment, and pays attention to the environmental publicity and education of employees, improves the environmental awareness of all staff, and strives to promote the synergistic interaction of pollution reduction and carbon reduction, and promotes the comprehensive green transformation of enterprise development.

Environment management system

3D Medicines abides by the Environmental Protection Law of the People's Republic of China, the Law of the People's Republic of China on Environmental Impact Assessment, the Law of the People's Republic of China on the Prevention and Control of Atmospheric Pollution, the Law of the People's Republic of China on Prevention and Control of Water Pollution, the Law of the People's Republic of China on the Prevention and Control of Environmental Solid Waste Pollution, the Law of the People's Republic of China on the Prevention and Control of Environmental Noise Pollution and other laws and regulations, and strictly implements the Environmental, Health and Safety (EHS) Manuals, and standard operating procedures for policies and economics.

3D Medicines standardizes the resource management of the Company's operation, production and daily office work, actively promotes energy conservation and emission reduction, and establishes the 3D Medicines Environmental Management System for laboratory environmental management, strengthens the management and supervision of hazardous waste, and effectively performs the main responsibility of the Company's ecological environmental protection.

3D Medicines regularly audits the major indicators related to resource consumption, clean production and environmental management system, conducts environmental impact assessment and review of eligible renovation and expansion projects, and performs internal inspection and environmental audit of environmental protection problems and environmental compliance in the form of on-site investigation and special inspection.

In 2022, the Company had no major environmental problems or environmental protection punishments.

Environmental management objectives

3D Medicines sets environmental management objectives as the primary focus of environmental protection:

(1)Reduce the density of electricity and water consumption;

(2)Advocate green office, make full use of natural lighting, and provide air conditioning energy-saving solutions;

(3)Strictly abide by the implementation standards for laboratory "three wastes" treatment;

(4)Provide ESG related training to employees (at least 2 working days of training for each employee per year).

The factory under 3D Medicines has formulated the Electricity Conservation Management System, which stipulates that natural light should be the first choice for lighting, solar energy lamps or green energy-saving lighting lamps should be selected, and advanced power technology should be used to improve energy utilization; moreover, it has also formulated the Water-saving System, which stipulates that water-saving technologies and water-saving appliances should be used to improve the efficiency of water use, strengthen the management of water use, and increase the recycle rate of flushing water; and it has established the air conditioning use management system, set temperature threshold, implemented unified control and management of air conditioning start and stop, and rationally used building structure and orientation, and building wall materials, so as to enhance the internal insulation effect.

Green advocacy

3D Medicines is committed to reducing the negative impact on the environment through energy saving and sustainable development, actively advocating the concept of paperless office, and enhancing employees' awareness of energy saving and environmental protection through internal publicity and public benefit activities on environmental protection, and encouraging employees to develop a moderate saving, green and low-carbon work and life style (starting from little things, pay attention to electricity saving, water saving, paper saving, and green travel in daily office).

In order to further enhance employees' awareness of environmental protection and make contributions to environmental protection, the Company organized a tree-planting activity and invited the participation of all employees. The Company chose an area without any vegetation to plant trees, and we hope that we could turn the wasteland into a green forest through our joint efforts, adding beauty to the community.

The Company's employees participated the tree planting activity proactively and seriously. Regardless of the weather a little cold, they all maintained high enthusiasm, and cooperated and helped each other in completing the whole planting process.

Response to climate change

Actively responding to national policies, 3D Medicines practices the concept of sustainable development with practical actions, and controls greenhouse gas emissions in strict accordance with the relevant requirements of laws and regulations, contributing to the goals of carbon dioxide peaking and carbon neutrality.

Climate change

The increasingly aggravated global climate change has brought about challenges and opportunities for the Company to actively response to. In this context, the Company referred to the Task Force on Climate-related Financial Disclosures (TCFD) framework in 2022 to identify and assess the relevant climate risks and build a management system for climate change. By identifying the risks and opportunities related to climate changes, the Company made targeted response strategies to comprehensively enhance the climate adaptation capacity.

Meanwhile, 3D Medicines will also actively promote the development of low-carbon economy, reduce carbon emissions and promote sustainable development. 3D Medicines will continue to improve management, actively respond to the challenge of climate change, and contribute to the enterprise sustainable development.

Risk name	Risk description	Solutions
Policies and regulations	The government has issued stricter policies and regulations to address climate change and strengthen the compliance requirements of environmental management.	Closely follow up the latest update of environmental policies, and timely adjust the enterprise work plan; Take effective measures to carry out green research and practice; Actively promote energy conservation and emission reduction.
Reputation	In the context of dual carbon reduction targets, corporate actions to address climate change and support low-carbon transition will have an impact on corporate reputation and market performance. If failing to meet the public's expectations for low-carbon transformation, the company may suffer from pressure from public opinion, causing damage to corporate image and reputation.	Make corresponding plans to reduce carbon emissions; strengthen climate risk management; improve transparency on environmental achievements and future plans; enhance communication with stakeholders, listen to their opinions and suggestions, and respond to their concerns and problems in a timely manner; and increase investment in environmental protection.
Market risks	Increasing market attention on environmental products and services, affecting the demand for some products and services; failure to effectively meet consumer demand for green and low-carbon products; and rising costs of raw materials and energy.	Establish a green supply chain system to improve the efficiency of resource utilization; actively respond to national environmental protection policies.
Technical risks	Increased costs of equipment upgrade and development due to the R&D of innovative technologies, and weakened competitiveness of products in the same industry due to the failure to identify and apply low-carbon technologies in a timely manner.	Carry out technical risk assessment and management, identify and monitor technical risks; actively carry out technological innovation and R&D.
Acute physical risks	Physical losses and risks resulting from unexpected events, such as extreme climate events, natural disasters, and environmental accidents (e.g., typhoons, rainstorms, floods).	Establish an emergency response mechanism, strengthen the monitoring and early warning of acute physical risks; strengthen the management of facilities and assets, ensure their safety and reliability, and improve the ability to resist natural disasters and environmental accidents.
Chronic physical risks	Physical losses and risks resulting from the long-term and progressive effects of climate change (e.g. sustained high temperature).	Carry out comprehensive risk assessment, analyze the potential impact of chronic physical risks on the enterprise, and develop appropriate countermeasures; strengthen monitoring and early warning of climate change and environmental change.

GHG emission

Adhering to the concept of green development, 3D Medicines constantly improves the prevention and control measures of air pollution, and strictly abides by the Law of the People's Republic of China on the Prevention and Control of Air Pollution and other laws and regulations; in addition we also take low-carbon development as an important driving force to improve quality and efficiency under the new normal, strictly control the total emissions of greenhouse gases, and enhance the low carbon competitiveness.

The greenhouse gas emission sources generated within the physical boundaries of production, operation and office of 3D Medicines are called carbon emission sources, mainly including the two types of direct emission and indirect emission. Direct emission sources refer to the greenhouse gases from the combustion of fossil fuels, such as natural gas, liquefied gas, city gas, raw coal, diesel oil, gasoline and fuel oil. Indirect emission sources refer to the greenhouse gases from the electricity and steam of net purchase.

Indicator	Unit	2022	2021	2020
Direct emissions (Category 1)	tCO_2e	3,087.61	-	-
Indirect emissions (Category 2)	tCO_2e	659.21	357.67	55.37
Total GHG emission	tCO_2e	3,746.82	-	-
GHG emission intensity	tCO_2e/RMB10,000 revenue	0.07	-	-

Note: (1) Direct emissions (Category 1) refer to the greenhouse gas emissions from the combustion activities of fossil energy, such as coal, natural gas and oil and industrial production processes;

(2)Indirect energy emissions (Category 2) refer to greenhouse gas emissions from the purchased electricity and heat;

(3)The accounting of calculations is based on the HKEX Environmental, Social and Governance (ESG) Reporting Guide, and the National Development and Reform Commission's Guideline for Accounting and Reporting Greenhouse Gas Emission of Other Industrial Enterprises.

(4)The annual revenue data of 3D Medicines is from the H-share 2022 Annual Results Announcement and the disclosed Global Offering Prospectus.

Emissions management

3D Medicines attaches great importance to emissions management, strengthens the supervision of pollutant emissions, ensures the standard discharge of wastewater and exhaust gas, standardizes the management and disposal of solid waste, and continuously improves the environmental protection awareness of employees in green emission reduction.

Management concept and mechanism

3D Medicines strictly abide by the national and local environmental protection laws and regulations, such as the Law of the People's Republic of China on the Prevention and Control of Air Pollution, the Law of the People's Republic of China on the Prevention and Control of Water Pollution and the Law of the People's Republic of China on the Prevention and Control of Solid Waste Pollution, adheres to the optimization of industrial structure, takes the development of circular economy as the guidance, and continues to promote the Company's clean production and reduce the Company's waste emissions, and improve the overall added economic value of the Company.

Ambient air

According to the Functional Zoning of Ambient Air Quality in Shanghai (HHBF [2011] No. 250), the Company is located in a class II ambient air zone, where the basic pollutants shall be subject to the Ambient Air Quality Standard (GB3095-2012) and its revised single secondary standard; while other pollutants shall be subject to the recommended values in Appendix D of Technical Guidelines for Environmental Impact Assessment - Atmospheric Environment (HJ2.2-2018) and the Detailed Explanation of Comprehensive Emission Standards for Atmospheric Pollutants.

Surface water environment

According to the Functional Zoning of Water Environment Quality in Shanghai (Rev. 2011), the Company is located in a class V water quality area, and subject to the class V standard of the Surface Water Environment Quality Standard (GB3838-2002).

Exhaust gas emission standard

The exhaust gas emissions are mainly particulate matters, and shall be subject to the Control Standard of Particulate Matter for Construction (DB31/964-2016), with the specific indicators shown in Table 18.

Wastewater discharge standard

The wastewater discharge shall be subject to the corresponding standards for indirect discharge by biomedical R&D institutions in the Discharge Standard of Pollutants for Bio-pharmaceutical Industry (DB31/373-2010) in Shanghai, as detailed in Table 20.

Solid waste

The general industrial solid waste storage sites shall comply with the requirements of the Standard for Pollution Control of General Industrial Solid Waste Storage and Disposal Sites (GB18599-2001) and its amendment in 2013; Hazardous waste storage sites shall comply with the requirements of Standard for Pollution Control on Hazardous Waste Storage (GB18597-2001) and its amendment. The storage capacity of hazardous waste shall meet the relevant requirements of the Notice of Shanghai Municipal Bureau of Ecological Environment on Issuance of the Implementation Plan for Further Strengthening the Prevention and Control of Hazardous Waste Pollution in Shanghai (HHT (2020) No. 50).

Emissions

3D Medicines upholds the concept of source control, and formulates corresponding management mechanisms for specific pollutants. 3D Medicines reduces the impact on the surrounding ecological environment by regularly checking the compliance treatment of major pollutants, and taking measures to minimize the level of emissions. Meanwhile, it is also committed to promoting resource recycling and reuse, so as to minimize the negative impact on the environment. The Company's goal is to make contributions to the realization of sustainable development through continuous efforts.

3D Medicines carries out compliance treatment according to the standards for corresponding type of emissions, strictly manages harmful wastes in accordance with laws and regulations and the company's internal control files, and makes centralized disposal of waste hazardous chemicals to prevent harmful wastes from polluting the environment.

Hazardous wastes from Shanghai Laboratory of 3D Medicines include laboratory exhaust gas, waste water, noise pollution and solid waste.

Laboratory exhaust gas

It mainly from reagent development, cell culture, drug screening and wastewater treatment and other processes. The organic exhaust gas is collected by two fume hoods, and introduced into a set of exhaust treatment device (activated carbon adsorption device) on the roof through pipes. Design size of exhaust funnel: 351×290mm, design height: 23m; All air in the biosafety cabinet is processed by the high-efficiency filtration system in the cabinet and then circulated internally (removing biological activity). The exhaust gas from wastewater treatment device is discharged after treated by the activated carbon adsorption treatment device, with the design discharge height of 3m.

Wastewater

It mainly includes experimental wastewater, purified water drainage and domestic sewage. After collection, it is treated by wastewater treatment device and pumped to park sewage pipe network and then the municipal sewage network. The "adjusting tank +MBBR+MBR membrane + UV disinfection and sterilization" process is used in the wastewater treatment device, with the maximum design size of 5T/a.

Noise

The noise is mainly from the experimental process and the waste treatment device. The Company takes measures such as building sound insulation, soft connection between air ducts and equipment, and installation of mufflers at the exhaust port to reduce noise.

Solid waste

Solid waste is mainly from reagent R&D, cell culture or drug screening test and other experimental processes, of which hazardous waste mainly includes laboratory liquid waste, packaging waste, activated carbon waste, and the Company entrusts Shanghai Hazardous Waste Disposal Co., Ltd. for incineration disposal; and medical waste mainly includes infectious waste and other damaging waste, such as culture medium waste, serum waste, and waste disposable consumables. Shanghai Solid Waste Disposal Co., Ltd. is entrusted to dispose all solid waste above.

The waste from Beijing Innovative Pharmaceutical R&D Laboratory of 3D Medicines includes organic exhaust gas, waste water, organic waste liquid, solid waste, and laboratory waste, and multiple emission reduction measures are taken by the laboratory to reduce pollutant emissions.

Installation of fume hood and fume exhaust

There are more than 20 fume hoods and fume exhausts installed in the laboratory, and all experimental operations are carried out in the fume hoods. Moreover, 4 sets of activated carbon exhaust gas treatment equipment are installed in parallel on the roof of the laboratory. The volatile exhaust gas generated during the experiment is sent to 4 activated carbon purifiers through fume hood and fume exhaust, and then discharged through a 1×25m high exhaust funnel. In addition, the activated carbon is replaced regularly to guarantee the effectiveness of purification.

Installation of sewage treatment device

Sewage treatment device is installed on B1 of Experimental Building, and the process of "acid-base adjusting tank + REDOX +RO membrane + nano-filtration + photocatalytic oxidation" is used to treat the cleaning wastewater of experimental equipment and utensils. In addition, pipelines are laid in the laboratory to collect cleaning wastewater and convey to the sewage treatment device for treatment, and the treated wastewater is discharged into the municipal sewage pipe network.

Unified treatment by an entrusted third party with qualification

The waste liquid (waste acid, waste alkali, organic waste liquid), packaging waste (reagent bottles, kits, packaging boxes, packaging cases), organic solid waste (waste silica gel and etc.), and laboratory waste (waste glass, waste needles, waste paper, etc.) from the laboratory are all treated by a qualified third party entrusted by the Company in a unified manner.

3D Medicines Beijing Laboratory exhaust gas treatment device

3D Medicines Beijing Laboratory sewage treatment device

Indicator	Unit	2022	2021	2020
Total hazardous waste (including waste acid, waste alkali, waste solvent)	t	3.16	2.50	-

Sorting and recycling

Recycled materials

Online office

Mobile review and approval

The general solid waste from 3D Medicines mainly comes from office waste and household waste generated in production and operation. In order to effectively manage office waste and household waste, the Company has taken a series of sustainable measures. The impact of waste on the environment is reduced by sorting and recycling.

In addition, the Company encourages the use of reusable materials and containers, such as paper and plastic, to reduce waste generation, and saves related resources through online work, video conferencing, document sharing, online punching, and mobile approval.

Use of resources

Resources serve as the material basis for the existence and development of human society. Adhering to the development concept of environmental protection, energy saving and consumption reduction, 3D Medicines has been deeply grasping the internal relationship between energy development and ecological civilization construction, strengthening the management of hydropower, electric energy and other resources, comprehensively enhancing employees' awareness of saving within the Company, optimizing daily management, and making solid progress in the development of environmental protection and energy conservation.

Energy saving and consumption reduction

Strictly abiding by the provisions and requirements of laws and regulations such as the Law of the People's Republic of China on Energy Conservation, 3D Medicines always implements the concept of resource conservation in the enterprise production and operation, measures and monitors energy consumption, systematically records energy usage data, and standardizes energy management. Meanwhile, according to the national environmental protection laws, regulations, guidelines and policies, the Company has formulated the Management System for Energy Saving and the Management System for Water Saving in combination with its actual operation situation and development strategy, so as to constantly improve the energy management system, make rational use of resources, and improve the energy utilization rate.

The Xuzhou plant of 3D Medicines was under construction in 2022, and it is planned to be completed and put into trial production operation in 2023. The Company will prepare relevant environmental management system documents according to the actual operation situation of the plant in the future, and formulate and strictly implement energy-saving measures to reduce the consumption of electricity and water resources in the operation, and will further prepare the relevant environmental management system documents according to the operation of the plant.

Electricity-saving technical measures

- Employ advanced power technology to improve energy utilization and reduce energy consumption. Do not use mechanical and electrical products that have been declared obsolete by the country;
- Take natural light as the first choice for lighting, use green energy-saving lighting lamps, and select solar or LED lamps for factory road and landscape lighting.
- Establish the Management System for Electricity Saving in management, post electricity saving signs on switches and control boxes, implement after-shift inspection, and eliminate unmanned lighting.

Water-saving technical measures

- Use water-saving technologies and water-saving appliances to improve water use efficiency and save water resources;
- Strengthen water use management, and establish the Management System of Water Conservation; strengthen the maintenance of water use equipment, eliminate leakage and venting, and reduce waste;
- Recycle the supernatant of flushing water of construction, and regularly clean the sludge at the bottom to improve the utilization rate of flushing water.

Air-conditioning energy saving measures

- Establish the applicable management system of air conditioning, turn on the air conditioner for cooling when the room temperature is higher than 26 °C, with the temperature controlled not less than 24 °C; turn on the air conditioner for heating when the room temperature is lower than 20 °C, with the temperature controlled not higher than 24 °C;
- Implement uniformed management of the air conditioning start and stop control, and avoid unmanned operation.

Building energy conservation

- Reasonably determine the building type and direction, improve the building envelope, and reduce the heat transfer coefficient of external walls using new and efficient thermal insulation fire-proof material such as rock wool, glass wool, polystyrene plastics, polyurethane foaming plastic as well as composite walls for building walls;
- Effectively reduce the heat conduction between indoor air and outdoor air by installing sealing strips for doors and windows, and using low-radiation glass, and plastic doors and windows with good thermal insulation performance of glass;
- Reduce building energy consumption by using efficient thermal insulation materials on the roof of the plant, so as to achieve cost reduction and efficiency increase, and contribute to carbon neutrality target.

Energy management

3D Medicines always attaches importance to the importance of energy management for sustainable development, and strictly abides by the provisions of the Law of the People's Republic of China on Energy Conservation; moreover, it also focuses on reducing unit energy consumption, supporting energy conservation development, and improving energy efficiency, and implements standardized energy conservation supervision and management within the Company, and implements energy conservation throughout the whole process of production and operation, so as to promote comprehensive, coordinated and sustainable economic and social development.

Indicator	Unit	2022	2021	2020
Total electricity consumption	kWh	1,134,615	615,617	95,304
Energy efficiency	kWh/RMB 1,000 revenue	20.00	-	-

Note: (1) The statistical data above involve 3D Medicines and its physical production subsidiaries in China.

Water resources management

Strictly abiding by the provisions and requirements of relevant laws and regulations such as the Water Law of the People's Republic of China, 3D Medicines advocates the rational use of water resources, continuously improves the recycle rate of water resources, improves the water-saving awareness of employees by promoting the concept of water conservation, so as to boost the construction of water-saving industry.

Indicator	Unit	2022	2021	2020
Municipal water supply consumption	m^3	10,891.00	3,141.00	490.00
Barrelled water consumption	m^3	25.13	21.08	13.44
Bottled water consumption	m^3	0.88	0.88	
Total water consumption	m^3	10,917.01	3,162.96	503.44
Water consumption intensity	m^3/RMB 10,000 revenue	0.19	-	-

Note: (1) Water efficiency can reflect the revenue per ton of water resource output, namely, the larger the output value per unit of water resource, the higher the water efficiency.

(2) The annual revenue data of 3D Medicines is from the H-share 2022 Annual Results Announcement.

(3) The data only involves 3D Medicines and its main subsidiary factories in China.

Material management

By 2022, the business of 3D Medicines focused on drug R&D and clinical trials, and the materials were mainly used in the development and experiment of drug preparations.

Actively responding to the "Dual Carbon" goal, the Company strengthens the control of the consumption of all kinds of pharmaceutical materials and packaging materials, reduces unnecessary waste, and strengthens the recycling of packaging materials, and performs reasonable resource recovery of materials that cannot be recycled. The Company has maximized the resource environmental protection under the premise of ensuring safe operation and no pollution.

Green operation

Adhering to the concept of green development, and closely following the national “14th Five-Year Plan" strategy, 3D Medicines adheres to the development strategy of green operation, integrates the concept of green and low carbon into the production and operation and daily office, attaches importance to the environmental protection education of employees, and encourages employees to practice green office; improves the packaging materials of the Company's products to reduce energy consumption; and creates a green industry chain as the goal, and promotes the recycling of energy, so as to build an environmentally friendly enterprise.

Green office

The Company actively advocates green, low-carbon, Eco-friendly and economical office habits, and constantly improves employees' awareness of energy conservation and environmental protection.

Low-carbon operation

The Company pays attention to daily green office, namely, implementing paperless office starting from the bit by bit, strengthening the construction of collaborative office management system, implementing online approval, reimbursement and other processes, and minimizing the amount of paper. Meanwhile, online video conferencing is encouraged to replace on-site meetings and other office forms, so as to achieve low-carbon operation.

Save electricity

The indoor air conditioning temperature in the office area of the Company is not lower than 26°C in summer, and not higher than 20°C in winter.

Green electricity

The lights in office corridors, toilets and other public places are turned on at 8:00 am and kept off after work. Regular propaganda is carried out to cultivate good electricity saving habits, so that "all lights are turned off when people leave, and all machines are shut down when people leave".

Clean R&D

Sustainability and environmental responsibility are more important than ever in nowadays society. Green R&D in the pharmaceutical industry means the development of drugs with minimal impact on the environment. The Company adheres to the concept and practice of green environmental protection in the whole life cycle of drugs, including R&D, manufacturing, distribution and disposal, thus creating a better tomorrow for patients in multiple aspects including drug R&D and manufacturing.

Reduce building energy consumption

The building materials satisfying environmental protection requirements are used in the construction of R&D laboratories and factories, and sound insulation and heat insulation materials are used to minimize building energy consumption.

Laboratory building materials: The side tables, central tables, sink table cabinets, reagent cabinets, gas cylinder cabinets in the Company's labs are all made of steel, energy saving, environmental protection and low energy consumption.

Laboratory air conditioning system: The air conditioning fan, motor, steel plate, copper pipe and other parts are all of domestic high-quality brands, and all in line with the relevant national standards. The air conditioning units are provided with good corrosion resistance, heat preservation performance, and sound insulation and vibration isolation performance; the units are in smooth transmission, anti-corrosion and wear-resisting, and well sealed; The air duct is made of high quality non-pattern galvanized steel plate, with the thickness in line with the national standards. The air valve is PP air valve of high quality brand, which is a fast variable air volume regulating valve designed for the special requirements of chemical laboratory. there has been insulation treatment for outdoor fresh air, exhaust air, air supply pipes, valves, and mufflers, and the air conditioning system and the fresh air system work together to provide the room with appropriate air volume balance and indoor pressure. The reaction speed of various valves is rapid, achieving the rapid balance of air volume of fume hood and room, and effectively reducing energy loss.

Laboratory Fresh air risk control system of 3D Medicines (Beijing)

Laboratory fresh air system: Laboratory fresh air system: The variable air volume exhaust valve on the top of laboratory fume hood is quick reaction butterfly valve with an online flow measurement device. The dual control mode of displacement and comparison of measured air volume and demand air volume of the pipeline is employed, and the displacement sensor is used to quickly adjust the air volume, so as to reduce energy consumption. The control module is compatible with 485 communication interface, seamlessly connecting with the upper intelligent control system.

The fresh air handling unit is provided with variable frequency control. According to the measurement of the pressure in the air supply pipe, the start, stop and speed of the fan are controlled by the frequency converter, and the frequency of the fan is automatically adjusted. Meanwhile, a temperature sensor is installed at the fresh air outlet of the unit to monitor the fresh air temperature in real time, enabling the system to quickly adjust the control of the unit's function section.

Reduce power consumption

- Only use LED lights and energy saving appliances.
- Use energy saving equipment such as variable frequency air conditioner and variable frequency fresh air system.
- Set the corresponding temperature and humidity of air conditioner seasonally.
- Turn off all power and electrical appliances after work and on holidays.

3D Medicines Shanghai/Beijing laboratory air conditioning energy-saving tips

3D Medicines Shanghai/Beijing laboratory air conditioning energy-saving tips

Laboratory water saving measures

- Triple faucet is used in the laboratory, with the spout of pvc tip type, so as to improve the utilization efficiency of water and achieve energy efficient.
- During holidays, the laboratory strictly checks all switches and closes all water main valves.

Laboratory waste disposal

- The laboratory carries out corresponding environmental protection treatment of the waste generated, and classify and temporarily store the waste, and take protective measures in strict accordance with the Standard for Pollution Control on Hazardous Waste Storage (GB18597-2001), and the Standard for Pollution Control on the Storage and Disposal Site for General Industrial Solid Wastes (GB18597-2001) (GB18599-2001), and regularly appoint a qualified third-party disposal unit for professional treatment.

OUTLOOK

3D Medicines was listed on the Hong Kong Stock Exchange in 2022, marking that the concept of sustainable development, the fulfillment of social responsibility and the requirements for corporate governance of the Company would be officially under the supervision of the whole society, which will contribute to the establishment of a complete, compliant and professional ESG system, as well as the sustainable development and long-term stable competitiveness of the Company in the future.

In 2023, we will continue to take ESG corporate governance, innovative R&D, product liability, responsible operation, people first, environmental protection and public welfare as the 7 major management objectives, actively develop, optimize and improve the existing ESG management system, and deepen the implementation of ESG-related responsibilities.

We are actively improving the product launch speed and product liability management, and aiming to address unmet clinical needs with a high sense of responsibility. We will continue to strengthen supplier management, implement the responsibilities of all parties, and develop the upstream and downstream relationship of sustainable development.

We will dig deeply the requirements of employees, safeguard employee rights and interests, strengthen employee training, and help employees achieve their growth goals. We will actively engage in public welfare, and reflect the Company's social responsibility.

We will continue to protect the environment, set environmental goals, identify the waste of resources that can be saved, and cultivate the green office concept of all employees. We will also participate in the environmental protection activities, forest planting, and returning farmland to forest.

The Board of Directors of the Company will continue to incorporate ESG governance into the overall company strategy and operation management direction, optimize the ESG management framework, and coordinate the development with various stakeholders for win-win cooperation.

APPENDIX: HKEX ESG INDEX

Environmental, Social and Governance Indicators		Disclosure section
	Main Category A. Environment	
	Level A1: Emissions	
General disclosure	Disclosure about relevant exhaust gas and greenhouse gas emissions, discharges into water and land, hazardous and non-hazardous waste: (a)Policies; and (b)The information about the compliance with relevant laws and regulations that have a significant impact on the issuer.	Response to climate change: GHG emission Emission management: Management concept and mechanism
KPI A1.1	Emission types and relevant emission data.	Emission management: Emissions
KPI A1.2	Direct (scope 1) and indirect (scope 2) greenhouse gas emissions from energy sources (in tons), and (where appropriate) intensity (e.g. per unit of production volume, per facility). Scope 1 Emissions Scope 2 Emissions	Response to climate change: GHG emission
KPI A1.3	Total hazardous waste produced (in tons) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Emission management: Emissions
KPI A1.4	Total non-hazardous waste produced (in ton) and, where appropriate, intensity (e.g. per unit of production volume, per facility).	Emission management: Emissions
KPI A1.5	Description of the emission objectives set and the steps taken to achieve such objectives.	Emission management: Emissions
KPI A1.6	Description of the method to dispose of hazardous and non-hazardous wastes, waste reduction objectives set and the steps taken to achieve such objectives.	Emission management: Emissions
	Level A2: Use of Resources	
General disclosure	Policies on the efficient use of resources, including energy, water and other raw materials.	Use of resources: Energy saving and consumption reduction
KPI A2.1	Direct and/or indirect energy consumption by type (e.g. electricity, gas or oil) in total (KWh in '000s) and intensity (e.g. per unit of production volume, per facility).	Use of resources: Energy management
KPI A2.2	Water consumption in total and intensity (e.g. per unit of production volume, per facility).	Use of resources: Water resources management
KPI A2.3	Description of the energy use efficiency objectives set and the steps taken to achieve such objectives.	Use of resources: Water resources management
KPI A2.4	Description of any problems in obtaining the applicable water sources, the water use efficiency objectives set and the steps taken to achieve such objectives.	Use of resources: Water resources management
KPI A2.5	Total packaging material used for finished products (in ton), and, if applicable, proportion of per production unit.	Use of resources: Material management
	Level A3: Environment and natural resources	
General disclosure	Policies on minimizing the issuer's significant impact on the environment and natural resources.	Green operation
KPI A3.1	Description of significant impacts from business activities on the environment and natural resources and the actions taken to manage them.	Green operation: Green office Clean R&D
	Level A4: Climate change	
General disclosure	Identification and response to policies prepared for significant climate-related issues that have already had or may have an impact on the issuer.	Response to climate change: Climate change
KPI A4.1	Description of significant climate-related issues that have already had or may have an impact on the issuer and corresponding responsive actions.	Response to climate change: Climate change
	Main Category B. Society	
	Employment and Labor Practices	
	Level B1: Employment	
General disclosure	Relating to compensation and dismissal, recruitment and promotion, working hours, rest periods, equal opportunity, diversity, anti-discrimination, and other benefits and welfare: (a) Policy; and (b) The information about the compliance with relevant laws and regulations that have a significant impact on the issuer.	People first: Legal employment Employment diversity and equity
KPI B1.1	Total workforce by gender, employment type (full time or part-time), age group and geographical region.	People first: Employment diversity and equity
KPI B1.2	Employee turnover rate by gender, age group and geographical region.	People first: Employment diversity and equity
	Level B2: Health and safety	
General disclosure	Disclosure about providing a safe working environment and protecting employees against occupational hazards: (a) Policies; and (b) The information about the compliance with relevant laws and regulations that have a significant impact on the issuer.	People first: Health and safety
KPI B2.1	The number and ratio of work-related deaths annually in the past three years (including the reporting year).	People first: Health and safety
KPI B2.2	Lost days due to work injury.	People first: Health and safety
KPI B2.3	Description of occupational health and safety measures adopted, how they are implemented and monitored.	People first: Health and safety
	Level B3: Development and training	
General disclosure	Policies on improving employees' knowledge and skills for discharging duties at work.	People first: Employee training and development
KPI B3.1	The percentage of employees trained by gender and employee category (e.g. senior management, middle management, etc.).	People first: Employee training and development
KPI B3.2	Average training hours completed per employee by gender and employee category.	People first: Employee training and development

Environmental, Social and Governance Indicators		Disclosure section
	Level B4: Labor standards	
General disclosure	Disclosures about preventing child and forced labor: (a) Policy; and (b) The information about the compliance with relevant laws and regulations that have a significant impact on the issuer.	People first: Legal employment
KPI B4.1	Description of measures to review employment practices to avoid child and forced labor.	People first: Legal employment
KPI B4.2	Description of steps taken to eliminate such practices when discovered.	People first: Legal employment
	Level B5: Supply chain management	
General disclosure	Environmental and social risk policies for supply chain management.	Product liability: Supply chain management
KPI B5.1	Number of suppliers by geographical region.	Product liability: Supply chain management
KPI B5.2	Description of practices relating to engaged suppliers, number of suppliers where the practices are being implemented and how they are implemented and monitored.	Product liability: Supply chain management
KPI B5.3	Description of the practices used to identify the environmental and social risks at every stage of the supply chain and relevant implementation and monitoring methods.	Product liability: Supply chain management
KPI B5.4	Description of the practices used to promote the use of green products and services at the time of selecting suppliers and relevant implementation and monitoring methods.	Product liability: Supply chain management
	Level B6: Product liability	
General disclosure	Disclosure about health and safety, advertisement, label and privacy matters relating to products and services provided and methods of redress. (a) Policies; and (b) The information about the compliance with relevant laws and regulations that have a significant impact on the issuer.	Product liability: Quality management
KPI B6.1	Percentage of total products sold or shipped subject to recalls for safety and health reasons.	Product liability: Abnormal events and product recall
KPI B6.2	Number of products and services related complaints received and how they are dealt with.	Responsible operation: Complaint handling
KPI B6.3	Description of practices relating to safeguarding and protecting intellectual property rights.	Innovative R&D: Intellectual property management
KPI B6.4	Description of quality verification process and product recall procedures.	Product liability: Abnormal events and product recall
KPI B6.5	Description of consumer data protection and privacy policies and how they are implemented and monitored.	Responsible operation: Customer rights and interests

Environmental, Social and Governance Indicators		Disclosure section
	Level B7: Anti-corruption	
General disclosure	Disclosure about bribery, extortion, fraud and money laundering: (a) Policies; and (b) Compliance with relevant laws and regulations that have a significant impact on the issuer.	Responsible operation: Compliance and anti-fraud management
KPI B7.1	Number of concluded legal cases regarding corrupt practices brought against the issuer or its employees during the reporting period and the outcomes of the cases.	Responsible operation: Compliance and anti-fraud management
KPI B7.2	Description of preventive measures and whistle-blowing procedures, and how they are implemented and monitored.	Responsible operation: Complaining and whistle-blowing ways
KPI B7.3	Description of the anti-corruption training provided for the directors and employees.	Responsible operation: Training on combating corruption and upholding integrity as well as internal control risks
	Level B8: Community investment	
General disclosure	Policies on community engagement to understand the needs of the communities where the issuer operates and to ensure its business activities take into consideration the communities' interests.	Public welfare
KPI B8.1	Focus areas of contribution (e.g. education, environmental concerns, labor needs, health, culture, and sports).	Public welfare
KPI B8.2	Resources (e.g. money or time) contributed to the focus areas.	Public welfare

Referral Table

The Company, we	referred as	3D Medicines Inc. and its related subsidiaries.
IND	referred as	Investigational New Drug
PROC	referred as	Platinum-resistant ovarian cancer
AML	referred as	Acute myeloid leukemia
MPM	referred as	Malignant pleural mesothelioma
OC	referred as	Ovarian cancer
MM	referred as	Multiple myeloma
CDE	referred as	Center for Drug Evaluation, National Medical Products Administration
NMPA	referred as	National Medical Products Administration
CSCO	referred as	Chinese Society of Clinical Oncology
ESG	referred as	Environmental, Social and Governance
cGMP	referred as	Current Good Manufacturing Practice for Drugs
ELISA	referred as	Enzyme Linked Immunosorbent Assay
PCR	referred as	Polymerase Chain Reaction
XtalPi	referred as	XtalPi
GMP	referred as	Good Manufacturing Practices, the existing guidelines and regulations issued in accordance with the Drug Administration Law of the People's Republic of China, as part of quality assurance, are designed to minimize the risks of contamination, cross-contamination, confusion and errors in the manufacture of pharmaceutical products, and ensure that drugs subject to such guidelines and regulations are continuously manufactured and controlled in accordance with the quality and standards applicable to the intended use
GCP	referred as	Good Clinical Practice
SOP	referred as	Standard Operation Procedure
GDPR	referred as	General Data Protection Regulation

FORM OF READER'S FEEDBACK

Dear readers:

Hello!

Thanks for reading this report. We are sincerely looking forward to your valuable feedback and advise on the report so that we can continue to improve our work, enhance ESG management ability and upgrade ESG management standard! You may send us the questionnaire through mail or scan the questionnaire and send us a digital version through email. Your active feedback are most welcomed. Thank you!

Mailing Address:7 Liangshuihe 1st Street, Building 3-6, Yizhuang Biomedical Park, BDA, Beijing, China

Tel.:+86(10)6788 8635

E-mail:ir@3d-medicines.com

What kind of stakeholders of the Group do you work for?

□ Shareholder and Investor □ Employee □ Supplier □ Customer □ Government and Regulator

□ Community □ Partner □ Industry Association/NGO □ Others (Please specify)_____

Your overall rating of the Report:

□ Good □ Fair □ Average □ Poor

How do you rate the clarity, accuracy and completeness of the information and data disclosed in the Report?

□ Good □ Fair □ Average □ Poor

How do you rate the comprehensiveness of the economic responsibility undertaken by the Group reflected in the Report?

□ Good □ Fair □ Average □ Poor

How do you rate the comprehensiveness of the environmental responsibility undertaken by the Group reflected in the Report?

□ Good □ Fair □ Average □ Poor

How do you rate the comprehensiveness of the social responsibility undertaken by the Group reflected in the Report?

□ Good □ Fair □ Average □ Poor

Do you think the information provided in the Report is readable?

□ Good □ Fair □ Average □ Poor

What would you like to know that is not disclosed in the Report?

Your comments and suggestions on the ESG work and report preparation of the Group.